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1. REVIEW OF THE LITERATURE 
1.1. Progressive myoclonus epilepsies 
Progressive myoclonus epilepsies (PMEs) are a group of clinically and etiologically 
heterogeneous diseases, comprehending symptoms such as epileptic seizures, 
myoclonus, and progressive neurological degeneration with cognitive impairment 
(Marseille Consensus Group, 1990). The PMEs are rare, and most of them are 
autosomal recessively inherited. There are, however, also autosomal dominant and 
mitochondrially inherited forms, such as the Parry’s disease (CLN4B) and myoclonic 
epilepsy with ragged red fibers (MERRF). The disease onset of PMEs is often in 
childhood or in early adolescence, most giving a poor diagnose and usually leading to 
death of the patient within the first decades after onset (de Siqueira, 2010). The five 
most common PME disease types are Unverricht-Lundborg disease (EPM1/ULD), 
Lafora disease (LD/EPM2), neuronal ceroid lipofuscinoses (NCLs), MERRF, and 
sialidoses (Lehesjoki, 2003). 
The PME diagnoses have traditionally been based on clinical features, 
electroencephalography (EEG), and electron microscopy (EM) findings (Berkovic et al, 
1986), but nowadays they rely mainly on molecular genetic testing (Shahwan et al, 
2005). There is no cure for any of the PMEs (de Siqueira, 2010), but symptoms such as 
the epileptic seizures can be controlled by medication, even if progression of the 
diseases is inevitable. 
Up to 1% of all epileptic syndromes worldwide concerning children and adolescents 
belong to a PME disorder (de Siqueira, 2010), but the geographical distribution of the 
individual diseases is unequal. EPM1 is for example the most prominent PME disorder 
in Northern Europe, USA and Canada, whereas Lafora disease is the most common in 
Mediterranean countries, India, and in countries where consanguineous marriages are 
common (Delgado-Escueta et al, 2001).  
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Many of the PMEs are mis- or underdiagnosed in several countries due to the 
similarity of the clinical symptoms to more common epilepsy types (de Siqueira, 2010; 
Shahwan et al, 2005).  
 Unverricht-Lundborg disease (EPM1/ULD) 1.1.1
EPM1 (OMIM 254800) was initially described by Unverricht in 1891 (Unverricht, 1891) 
and by Lundborg in 1903 (Lundborg, 1903), and it is the most common PME type 
(Lehesjoki, 2003). The disease occurs with low frequency in all populations, but it is 
geographically more common in places with founder effect or in regions where 
consanguineous marriages are common (Genton, 2010), i.e. in Finland and in certain 
countries of the Western Mediterranean region (Magaudda et al, 2006). The incidence 
of EPM1 in Finland is 1:20 000 births per year (Norio & Koskiniemi, 1979), and there 
are about 200 diagnosed cases (Kälviäinen et al, 2008). Statistics are not available from 
other countries, and it seems like EPM1 is underdiagnosed in many of them due to the 
clinical heterogeneity of the symptoms and the similarity of its initial stages to other 
epilepsy types (De Haan et al, 2004). Until 1989, EPM1 was divided into two separate 
conditions, the Baltic and the Mediterranean epilepsies, of which the Baltic was 
considered to be more severe. However, in the Marseille meeting in 1989 both 
conditions were defined as the same (Marseille Consensus Group, 1990), and it was 
later discovered that possible differences in symptomatology are most likely due to 
environmental factors, such as the rehabilitative medication (Kälviäinen et al, 2008). 
1.1.1.1 Clinical features of EPM1 
EPM1 is autosomal recessively inherited and the age of disease onset is between 6 and 
16 years (Kälviäinen et al, 2008). Stimulus sensitive myoclonus has been reported as 
the first symptom in over 50% of EPM1 cases (Shahwan et al, 2005) and it has been 
described, together with generalized tonic-clonic epileptic seizures and a characteristic 
EEG, as the initial symptoms for EPM1 (Koskiniemi, 1986; Koskiniemi, 1987; Norio & 
Koskiniemi, 1979). 
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The stimulus-sensitive myoclonus is often triggered by light, sound, touch, and/or 
physical exertion and the jerks are disabling and resistant to therapy. The myoclonic 
jerks progress in severity during the initial years after disease onset, but they stabilize 
over time both in amount and severity, resulting in an increased tolerance in most 
patients (Genton, 2010; Kälviäinen et al, 2008). The epileptic seizures are infrequent in 
the beginning and vary in manifestation being focal, multifocal, or generalized, 
developing into a series of myoclonic seizures. Like the myoclonic jerks, the epileptic 
seizures increase both in amount and severity during the first 3-7 years after disease 
onset, but since the seizures can be treated with anti-epileptic drugs, they may in 
some patients be completely excluded (Koskiniemi, 1986; Koskiniemi, 1987; Norio & 
Koskiniemi, 1979). 
EPM1 progresses within a few years into ataxia, incoordination, dysarthria, and a 
constant intention tremor. About one third of the patients become severely disabled 
and wheelchair bound, being unable to eat or drink without assistance (Kälviäinen et 
al, 2008). Most of the patients have, however, fluctuations with both good and bad 
days (Genton, 2010; Kälviäinen et al, 2008), and it may take up to years or even 
decades before these patients lose their ability to walk (Kälviäinen et al, 2008). The 
cognition of EPM1 patients remains rather intact for a long time after disease onset, 
but over time a mild decline in intellectual performance starts to manifest. Depression 
and other psychiatric symptoms are very common amongst EPM1 patients, due to 
which, psychosocial rehabilitation is one of the most important supporting therapies 
(Kälviäinen et al, 2008).  
The clinical picture and progression rate of EPM1 varies both between and inside 
families (Kälviäinen et al, 2008). Some mild forms of EPM1 do not follow the full 
symptomatology, sometimes leading to a delayed diagnosis or the disease to be 
misdiagnosed. EPM1 itself is not fatal and due to effective therapies, the life 
expectancy of today’s patients is only slightly shorter than the general populations 
(Lehesjoki, 2002). 
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1.1.1.2 Pathogenesis 
Neuropathological studies of EPM1 patients are limited, but post-mortem analyses 
have revealed both atrophy and gliosis in the brain, especially in the cerebellum, 
thalamus, frontotemporal cortex, and hippocampus (Cohen et al, 2011; Haltia et al, 
1969; Koskiniemi et al, 1974). Voxel-based morphometry and cortical thickness 
analyses have shown regional thinning in the sensorimotor, visual, and auditory 
cortical areas of EPM1 patients (Koskenkorva et al, 2009; Koskenkorva et al, 2012). The 
thinning increases with the disease, and it is correlated with the degree of the motoric 
symptoms that the patients present (Koskenkorva et al, 2009; Koskenkorva et al, 
2012), i.e. ataxia and dysarthria. The loss of γ-aminobutyric acid (GABA) -ergic Purkinje 
cells and non-specific degenerative changes in the cerebellar cortex that have been 
observed in histopathological examinations (Eldridge et al, 1983) translates into 
functional disabilities in motoric tasks of the patients. Neuronal cytoplasmic inclusions, 
positive for stainings with the lysosomal marker CD68 and the lysosomal protein 
cathepsin B, have also been detected (Cohen et al, 2011). 
The skeletal characteristics are also altered in EPM1 patients. The first report of 
increased scull thickness, scoliosis, and osteoporosis was published by Koskiniemi et al. 
(1974), but a more detailed report of progressive thickening of the cranial bones, 
thoracic and lumbar scoliosis, ossicles in feet, and arachnodactyly has not been 
reported until recently (Korja et al, 2007; Suoranta et al, 2012). 
 The cystatin B gene 1.1.2
The gene underlying EPM1, cystatin B (CSTB, OMIM 601145) (Figure 1), on 
chromosome 21q22.3 (Lehesjoki et al, 1991) encodes for an intracellular cysteine 
proteinase inhibitor, cystatin B (CSTB) (Pennacchio et al, 1996). The gene has five 
putative transcripts of which one is known to be protein coding (Joensuu et al, 2007). 
The main transcript has three exons which are translated into 98 amino acids. 
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1.1.2.1 Mutations in CSTB 
Fourteen loss-of-function mutations in the CSTB gene underlying EPM1 have been 
described (Bespalova et al, 1997a; Canafoglia et al, 2012; De Haan et al, 2004; Erdinc 
et al, 2010; Joensuu et al, 2007; Kagitani-Shimono et al, 2002; Lafreniere et al, 1997; 
Lalioti et al, 1997a; Lalioti et al, 1997b; Pennacchio et al, 1996; Pinto et al, 2012; 
Virtaneva et al, 1997). The most common mutation is a 12-nucleotide long dodecamer 
expansion repeat (5’-CCCC GCCC CGCG-3’) in the promoter area of the gene (Lalioti et 
al, 1997b), leading to unstable initiation of transcription and a significantly reduced 
gene expression with less than 10% of CSTB mRNA produced (Joensuu et al, 2007). The 
dodecamer repeat is polymorphic and exists in the healthy population in 2-3 copies, 
while EPM1-associated alleles contain at least 30 copies. The number of expansion 
repeats is in general not correlated with the severity of the disease symptoms (Lalioti 
et al, 1998), but patients with more than 68 repeats on one allele have both an earlier 
onset of the symptoms and higher myoclonus rating scores in comparison to patients 
with 68 repeats or less (Hyppönen et al, unpublished). 
The remaining 13 EPM1-associated mutations affect splice sites, change amino acids, 
or are predicted to express a truncated protein (Joensuu et al, 2008). The identified 
CSTB mutations are summarized in Table 1 and their positions are illustrated in Figure 
1. 
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Table 1.  The identified mutations in the CSTB gene underlying EPM1. Modified from 
Joensuu et al, 2008 
 
Mutation Position of mutation/ 
mutation type 
Predicted 
consequence on 
protein level 
 
Reference 
Dodecamer repeat 
expansion 
5' UTR/expansion Reduced CSTB 
expression 
Lafreniere et al, 1997; 
Lalioti et al, 1997b; 
Virtaneva et al, 1997 
c.10G>C Exon 1/missense p.Gly4Arg Lalioti et al, 1997a 
c.66G>A Exon 1/splice site? p.Gln22Gln Pinto et al, 2012 
c.67-1G>C Intron 1/splice site p.delVal23_Lys56 Bespalova et al, 
1997a; Lafreniere et 
al, 1997; Lalioti et al, 
1997a; Pennacchio et 
al, 1996 
c.125C>A Exon 2/nonsense p.Ser42Ter Erdinc et al, 2010 
c.136C>T Exon 2/nonsense p.Gln46Ter Canafoglia et al, 2012* 
c.149G>A Exon 2/missense p.Gly50Glu Joensuu et al, 2007 
c.168T>A Exon 2/splice site Aberrant splicing? Kagitani-Shimono et 
al, 2002 
c.168 + 1_18del Intron 2/deletion p.delVal23_Lys56 
p.Val57GlufsTer28 
Joensuu et al, 2007 
c.168+2_168+21delinsAA Intron 2/deletion + 
insertion 
? Canafoglia et al, 2012* 
c.169–2A>G Intron 2/splice site Aberrant splicing? De Haan et al, 2004; 
Lafreniere et al, 1997; 
Pennacchio et al, 1996 
c.202C>T Exon 3/nonsense p.Arg68Ter De Haan et al, 2004; 
Lafreniere et al, 1997; 
Pennacchio et al, 1996 
c.212A>C Exon 3/missense p.Gln71Pro De Haan et al, 2004 
c.218_219delTC Exon 3/deletion p.Leu73fsTer3 Bespalova et al, 
1997b; Lafreniere et 
al, 1997; Lalioti et al, 
1997a 
*Discrepancy in position of mutations in article. Positions confirmed by Elena Gennaro, 
personal communication (22.4.2013) 
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Figure 1. The identified CSTB mutations presented according to their position and 
mutation type. UTR = untranslated region, IVS = intervening sequence, EX = exon. Modified 
from Joensuu et al, 2008  
 
About 90% of all EPM1 patients and 99% of the Finnish patients carry the expansion 
repeat allele (Kälviäinen et al, 2008), to which most patients are homozygous. The 
remaining reported patients are compound heterozygous for the expansion and one of 
the other mutations, with the exception of two cases (Lalioti et al, 1997a; Pinto et al, 
2012), who are homozygous for a missense (c.10G>C) or a splice site mutation 
(c.66G>A). Compound heterozygous patients with the expansion and the c.202C>T 
mutation have been reported to have more severe symptoms than patients 
homozygous for the expansion mutation (Koskenkorva et al, 2011). The nonsense 
mutation c.202C>T causes an early termination codon and lack of functional CSTB 
protein, and therefore there is even less functional CSTB protein produced in 
comparison to <10% from the repeat expansion allele (Koskenkorva et al, 2011). 
 The cystatin B protein 1.1.3
The CSTB protein belongs to the type 1 cystatin family, which, together with type 2 
cystatins and kininogens, belongs to the cystatin superfamily. The superfamily contains 
proteins rich in cystatin-like sequences and many of its members, such as CSTB, 
function as cysteine protease inhibitors (Rawlings & Barrett, 1990).  
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CSTB is ubiquitously expressed, and its cellular localization is dependent on the 
developmental stage of the cell. CSTB is located mainly in the nucleus in proliferating 
cells, whereas in mature cells it is mainly found in the cytoplasm and associated with 
lysosomes (Alakurtti et al, 2005; Čeru et al, 2010b). Higher expression levels of CSTB 
have been observed in cerebellar Purkinje cells and in Bergmann glia in the human 
adult central nervous system (CNS) (Brännvall et al, 2003), and also in cerebellar 
oligodendrocyte progenitor cells in the rat CNS (Riccio et al, 2005). 
The full-length CSTB protein consists of a single polypeptide chain without disulphide 
bonds or carbohydrate side chains, and it folds into a neutral protein with a molecular 
weight of 11 kDa (Järvinen & Rinne, 1982; Ritonja et al, 1985). The schematic structure 
of the CSTB protein is presented in Figure 2. 
 
Figure 2.  The schematic structure of the human cystatin B protein consists of a five-
stranded beta-sheet (silver) wrapped around a five-turn alpha-helix (purple). The human 
CSTB contains also a carboxy-terminal strand, which runs in parallel with the convex side of 
the beta-sheet Stubbs et al, 1990. 
Modified from: http://bioch.szote.u-szeged.hu/astrojan/protein/pictures/cystat3.gif 
 
CSTB counteracts lysosomal protease activity, i.e. papains and certain cathepsins, both 
in vitro (cathepsins B, H, S, L and K) (Brömme et al, 1991; Green et al, 1984; Laitala-
Leinonen et al, 2006), and in vivo in lymphoblastoid cells (cathepsins B, S, and L) (Rinne 
et al, 2002). Cathepsins reside mainly in the lysosomes, but they are hypothesized to 
leak out to the cytosol, where they are inhibited by CSTB (Rinne et al, 2002). The 
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association between CSTB and cathepsins is tight, but reversible, and it is mediated by 
non-covalent forces via the highly conserved QVVAG (Gln-Val-Val-Ala-Gly) sequence in 
CSTB, forming the first hairpin loop at its N-terminus (Stubbs et al, 1990). The 
cathepsins possess several intra- and pericellular catalytic roles, in which the inhibitory 
function of CSTB has particular importance.  As an example, in proliferating cells in 
vitro, the loss of CSTB-mediated inhibition of cathepsin L in the nucleus makes cells 
enter the S phase earlier, thereby speeding up the cell cycle (Čeru et al, 2010a). CSTB 
participates also in inhibiting bone resorption in vitro by downregulating the activity of 
cathepsin K in osteoclasts (Laitala-Leinonen et al, 2006). 
 The cystatin B deficient (Cstb-/-) mouse 1.1.4
A mouse model for EPM1 was created by targeted disruption of the Cstb exon 1 
(Pennacchio et al, 1998) leading to loss-of-function of the gene, thereby mimicking the 
CSTB mutations in EPM1 patients. 
The Cstb-/- mice are born with no visible difference to wild type (wt) mice, and after 
weaning, at 1-3 months of age, they have the same body size, grooming behavior, 
coordination and strength as the control mice (Pennacchio et al, 1998). The Cstb-/- 
mice, however, develop myoclonic seizures during sleep at one month of age, 
consisting of twitches in the whiskers, ears, and the tail, leading to facial spasms and 
shaking of the torso and the limbs. The attacks last from a few seconds up to several 
minutes, and they usually end with a large myoclonic outburst (Pennacchio et al, 
1998). Worsening of the myoclonus is paralleled with decreased stainings with the γ-
aminobutyric acid (GABA) terminal density marker, vesicular GABA transporter (VGAT) 
in the cortex, indicating a reduction in GABA terminals, as it has been reported in 8 
months old Cstb-/- mice (Buzzi et al, 2012). The reduced amount of GABA interneurons 
leads to loss of inhibition and hyperexcitability in the cortex, which might contribute to 
the myoclonic seizures (Buzzi et al, 2012). 
At six months of age the Cstb-/- mice develop a mild ataxia which gets progressively 
worse (Pennacchio et al, 1998). The ataxia phenotype has been associated with loss of 
cerebellar granule cells, supported by both histopathological findings (Pennacchio et 
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al, 1998) and stereological analyses (Tegelberg et al, 2012). Atrophy of the cortex and 
the cerebellum in Cstb-/- mice is observed from two months of age, reaching an almost 
50% volume loss by the age of six months (Tegelberg et al, 2012). Positive terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainings have also 
indicated that the cerebellar granule neurons of Cstb-/- mice are in an apoptotic state 
(Pennacchio et al, 1998; Shannon et al, 2002). Double knockout mice for Cstb and 
cathepsin B (Ctsb) (Cstb-/-/Ctsb-/-) present with less TUNEL positive cerebellar granule 
neurons and milder neurological symptoms, suggesting that the described EPM1 
symptoms in mouse are at least partly mediated through CTSB (Houseweart et al, 
2003). 
Widespread gliosis has been observed in the brains of older (16-18 months) Cstb-/- 
mice (Shannon et al, 2002), but also in other animal models with epilepsy as 
phenotype (Avignone et al, 2008; Taniwaki et al, 1996). Microglial activation has been 
reported to occur after epileptic seizures (Taniwaki et al, 1996), but Tegelberg et al. 
showed increased F4/80 positive cells in Cstb-/- mice indicating activation of microglia 
already at postnatal day 14 (P14). This was followed by increased GFAP positive cells at 
one month of age, indicating activation of astroglia and suggesting an inflammation 
phenotype already before any of the previously described symptoms of EPM1 start to 
manifest (Tegelberg et al, 2012). The progression of the symptoms and the 
histopathological changes in the Cstb-/- mouse are shown in Figure 3.  
The genetic background of the mice affects the severity of the symptoms, i.e. the 
strain 129Sv (seizure prone) is more affected than the cross C57BLx129Sv (seizure 
resistant). Only Cstb-/- mice in the 129Sv background develop myoclonic seizures, while 
ataxia and abnormalities in brain, such as neural loss and gliosis, are seen in both 
backgrounds (Pennacchio et al, 1998; Shannon et al, 2002). Photosensitivity, tonic-
clonic epileptic seizures, myoclonic jerks while being awake, or an abnormal EEG have 
not been detected in Cstb-/- mice in neither background (Pennacchio et al, 1998). 
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Figure 3.  The symptomatic and histopathological findings in the Cstb-/- mouse. 
Adapted from Tegelberg et al, 2012 with permission of Wolters Kluwer Health 
 
1.1.4.1 Exon array analysis from primary microglia of P5 Cstb-/- mice 
Histopathological data from the brain of Cstb-/- mice revealed early and progressive 
activation of microglia (Tegelberg et al, 2012). Therefore, an exon array analysis (Exon 
array 1.0 ST) was conducted from the cultured primary microglia of postnatal day 5 
(P5+14DIV) Cstb-/- mice, in order to study gene expression profiles (Körber et al, 
unpublished). Downregulation of several interferon stimulated genes (ISGs) was 
detected, and the downregulation of the genes signal transducer and activator of 
transcription 1 and 2 (Stat1 and Stat2), and interferon regulatory factor 9 (Irf9) 
suggested an altered Janus kinase (JAK)/STAT signaling pathway in the Cstb-/- mice 
microglia (Körber et al, unpublished). Table 2 summarizes selected genes and their 
expression levels from the exon array analysis. 
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Table 2.  The relative gene expression profile from P5 Cstb-/- mice microglia. Modified 
from Körber et al, unpublished. 
 
Fold change Gene symbol Gene description 
-9,3 Cstb cystatin B 
-2,7 Stat1 signal transducer and activator of transcription 1 
-2,5 Stat2 signal transducer and activator of transcription 2 
-1,6 Irf9 interferon regulatory factor 9 
 
 Microglia 1.2.
Microglia are resident macrophages and the predominant immune cells of the CNS. 
They regulate the immunological response to physiological and pathological conditions 
in the brain, which is shielded by the blood brain barrier (BBB). During conditions such 
as inflammation, lesions, and neurological disorders, the BBB becomes leaky and other 
immune cells, such as leukocytes, invade the CNS (Brown & Neher, 2010; Liu & Hong, 
2003).  
Microglia can be in a resting, an activated, or a phagocytic state, depending on the 
present microenvironment. The states differ from each other both structurally and 
functionally, and Figure 4 presents the main structural differences. 
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Figure 4.  The microglial morphology is a hallmark for their activation state. Modified 
from Orr et al, 2002 
 
The resting microglia has a highly branched and ramified morphology, and it is the 
predominant form of microglia in the healthy CNS. The resting microglia does not have 
phagocytic activity, but it is highly motile, surveying its microenvironment with its 
processes (Kreutzberg, 1996; Nimmerjahn et al, 2005). When triggered by an 
environmental signal, the resting microglia becomes activated and starts expressing an 
amoeboid phenotype. The activated form of microglia has phagocytic activity, and it 
scavenges dead cells in the brain and releases immunoeffector molecules (Kreutzberg, 
1996; Nakajima & Kohsaka, 2001). If the environmental signal persists, the microglia 
transform to the third, the most active, phagocytic form, which is large and has a 
round cell shape. Both the activated and the phagocytic form express major 
histocompatibility complex (MHC) class II molecules and present antigens, triggering 
additional immune related responses (Brown & Neher, 2010; Czeh et al, 2011; 
Nakajima & Kohsaka, 2001). This activation of the adaptive immune system is an 
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important function of the acquired immune system (Orr et al, 2002), which is crucial 
for healing, but can be neurotoxic when prolonged (Czeh et al, 2011; Liu & Hong, 
2003). 
Epileptic seizures and ageing lead to higher microglial activity and sensitivity, causing 
microglial reactivity (Avignone et al, 2008; Beach et al, 1995; Czeh et al, 2011). 
Hyperactive microglia has been observed in certain neurodegenerative disorders, such 
as Alzheimer´s disease (AD), Parkinson´s disease (PD) (Liu & Hong, 2003; McGeer et al, 
1988), and multiple sclerosis (MS) (Jack et al, 2005). 
 Janus kinase (JAK)/Signal transducer and activator of transcription 1.3.
(STAT) signaling pathway 
Viruses, bacteria and some tumors activate the innate immune system, leading to 
cytokine secretion from lymphocytes. These cytokines, in particular interferon alpha 
(IFN-α), - beta (IFN-β), and - gamma (IFN-γ), mediate the activation of the subsequent 
type I and type II interferon signaling cascades via the JAK/STAT signaling pathway, 
leading to transcriptional activation of gene expression (Darnell et al, 1994; Liu et al, 
1998b). 
1.3.1. Signal transducer and activator of transcription (STAT) 1 and 2   
The signal transducer and activator of transcription (STAT) –genes form a family, which 
in mammals comprises seven members, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, 
and STAT6. STATs activate the transcription of genes involved in cell growth, 
differentiation, apoptosis, and immune responses (Lim & Cao, 2006). All STAT proteins 
share similar structural motifs, including a central DNA-binding domain (DBD), a Src 
homology 2 (SH2) -domain, and a tyrosine residue (Y701) at the carboxy-terminal (Lim 
& Cao, 2006). The STAT1 (OMIM 600555) and STAT2 (OMIM 600556) genomic loci are 
at 2q32.2 and 12q13.3, respectively. STAT1 has two isoforms, STAT1α (84 kDa), and 
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STAT1β (91 kDa) (Baran-Marszak et al, 2004), whereas STAT2 has only one known 
isoform (113 kDa) (Fu et al, 1990). 
STAT1 and STAT2 are regulated on phosphorylation level by the activity of the kinases 
JAK1, TYK2, and several dephosphorylating protein tyrosine phosphatases (PTPases). 
STAT1 is directly inhibited in vitro by protein inhibitor of activated STAT1 (PIAS1) in the 
nucleus, which blocks the DNA binding region of STAT1 (Liu et al, 1998a). PIAS1 has 
also been observed to upregulate the CSTB promoter activity in the African green 
monkey kidney cell line, COS-1 (Ilmarinen et al, 2008). However, similar experiments in 
the murine macrophage cell line, RAW264.7, have revealed an opposite effect of PIAS1 
by downregulating the CSTB promoter activity (Körber et al, unpublished). PIAS1 
interacts also in vitro with the transcriptional regulator autoimmune regulator (AIRE), 
which has been shown to strongly repress the CSTB promoter in COS-1 cells (Ilmarinen 
et al, 2008). 
All STATs are also indirectly regulated by suppressor of cytokine signaling (SOCS) 
proteins, which inhibit the kinase activity of JAKs (Krebs & Hilton, 2001). 
1.3.2. Interferon regulatory factor 9 (IRF9) 
The interferon regulatory factor 9 (IRF9), also known as interferon (IFN) stimulated 
gene factor 3γ (ISGF3γ) or p48, is encoded by the IRF9 gene (OMIM 147574) on locus 
14q11.2, and it belongs to the family of interferon regulatory factors (IRFs) (Reich, 
2002). The ten members of the IRF family (IRF1-10) activate transcription of interferon 
stimulated genes inducing cell growth, proliferation, differentiation, apoptosis, and 
immune responses (Ousman et al, 2005).  
Gene expression of IRFs may be constitutive, induced, and tissue-specific, and it is 
often associated with viral infections or tumorigenesis. Interferons induce the 
expression of most IRFs, which in the nucleus regulate gene expression. The 
expression of IRF3 and IRF9 is, however, relatively constant in most cells and their 
activity is solely regulated by redistribution between the nucleus and the cytoplasm 
(Reich, 2002; Savitsky et al, 2010). IRF3 and IRF9 do not regulate the activity of ISGs 
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per se, but function only when in complex with other, non-IRF proteins, such as the 
STATs (Reich, 2002). 
1.3.3. The Interferon-stimulated gene factor 3 (ISGF3) -complex  
The interferon-stimulated gene factor 3 (ISGF3) –complex is an activator of 
transcription of type I (IFN-α, IFN-β) ISGs during viral activation and drives the cell to 
an antiviral state with reduced cellular proliferation and protein synthesis (Schindler et 
al, 1992). STAT1, STAT2, and IRF9 build the ISGF3 –complex. 
Interferon secretion from lymphocytes and their binding to their specific receptor 
units initiate an intracellular signaling cascade, the JAK/STAT signaling pathway (Figure 
5). The receptor unit of type I IFN receptor (IFNAR) is facing to the extracellular space 
and it consists of two distinct transmembrane subunits, Interferon receptor 1 (IFNAR1) 
and Interferon receptor 2 (IFNAR2) (de Weerd et al, 2007). The receptor subunits do 
not have a phosphorylation activity per se, therefore they are pre-associated with the 
JAK1 and TYK2 kinases (de Weerd et al, 2007; Reich, 2007), which phosphorylate the 
carboxy-terminal tyrosine residues (Y701) of free cytoplasmic STAT1 and STAT2. Upon 
phosphorylation, the STATs undergo a conformation change and form heterodimers at 
their phosphotyrosine and SH2 domains (Reich, 2007). Unphosphorylated IRF9 binds 
to the phosphorylated STAT1-STAT2 heterodimer at the amino terminal coiled-coil 
region of STAT2, and forms the ISGF3 complex. Dimerization of STATs reveals a nuclear 
localization signal (NLS), which binds to importin-α receptors in the cytoplasm. 
Importin-α mediates the translocation of the ISGF3 complex to the nucleus via 
importin-β receptors through the nuclear pore complex (NPC), which spans across the 
nuclear membrane. The translocation is an active process mediated by the small 
guanosine triphosphate hydrolase (GTPase) Ran (Fagerlund et al, 2002; Liu et al, 
1998b; Sekimoto et al, 1996). The NLS is unrevealed in monomeric STAT proteins 
keeping their localization mainly cytoplasmic when in a latent, unphosphorylated state 
(Reich, 2007). 
In the nucleus, the ISGF3 complex binds to DNA at interferon stimulated response 
elements (ISREs) (Gutch et al, 1992) in the promoter area of ISGs, and activates 
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transcription of these genes via the carboxy-terminal transactivation domain of STAT2 
(Fu et al, 1992; Gutch et al, 1992). STAT2 requires a sequence-specific part of ISRE for 
transcriptional activation, and is unable to form stable interactions with DNA without 
STAT1 (Frahm et al, 2006).  
 
Figure 5.  The type I interferon mediated signaling cascade leads to transcription of 
antiviral genes in the cell. Modified from Dropulic & Cohen, 2011    
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 Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) 1.4.
The chemical compound nitric oxide (NO) is an important signaling molecule in the 
body, participating in i.e. vasodilatation, neurotransmission, inflammatory responses, 
and apoptosis (Chan & Riches, 2001; Gao et al, 1997; Kröncke et al, 1997; Martin et al, 
1994). Microglia produce and release NO during inflammation, triggering subsequent 
immune related responses.  
NO is produced by nitric oxide synthase (NOS) as a by-product in the arginine-citrulline 
pathway (Figure 6), where L-arginine is converted to citrulline (Martin et al, 1994). 
Neurons are highly susceptible to the effects of NO (Aquilano et al, 2011; Kröncke et 
al, 1998), and therefore it is one of the most strictly regulated molecules, being 
spatiotemporally regulated by several mediator proteins (Gao et al, 1997; Kröncke et 
al, 1998). The cerebella of Cstb-/- mice were shown to be sensitized to oxidative stress 
(Lehtinen et al, 2009), suggesting that Cstb is associated with regulation of the redox-
homeostasis. 
 
Figure 6.  The arginine-citrulline pathway produces nitric oxide as a by-product 
 
The NOS gene has three isoforms, neuronal NOS (NOS1, nNOS), inducible NOS (NOS2, 
iNOS), and endothelial NOS (NOS3, eNOS). The inducible form, iNOS, is activated in 
response to i.e. pathogenic attacks, resulting in long-term innate immunological 
responses (Brosnan et al, 1997). The human iNOS gene is located on chromosome 
17q11.2, and it has 27 exons (Xu et al, 1996). The promoter area of iNOS is one of the 
longest and most complex known, indicating a tight control of gene expression 
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(Kröncke et al, 1998). In the human brain, iNOS is expressed in astrocytes and in 
microglia, but also in neurons during their early developmental stages (Heneka & 
Feinstein, 2001). 
The two other NOS isoforms, nNOS and eNOS, participate in short-term events such as 
neurotransmission and vasodilatation. The balance between the short-term and the 
long-term NO production gives the basis for the physiological vs. pathophysiological 
actions of NO, which is thought to play an important role in human neurodegenerative 
diseases (Brosnan et al, 1997). This is supported by the observation that neuronal iNOS 
is not expressed in the healthy adult brain, but re-expression with increasing age and 
age-related neurological disorders has been observed (Heneka & Feinstein, 2001). The 
activation signals for induction of iNOS are cell- and species specific, and the 
expression starts late, hours after the initial stimuli (Brosnan et al, 1997; Koprowski et 
al, 1993; Kröncke et al, 1998). In order to produce massive amounts of NO, iNOS 
requires interferon induced activation of the cell.  
The two main pathways which are involved in the transcriptional control of iNOS are 
the IFN-γ induced JAK/STAT signaling pathway and the nuclear factor of kappa light 
polypeptide gene enhancer in B cells (NF-κB) pathway. Homodimerized 
phosphorylated STAT1α complexes translocate to the nucleus and bind to the 
interferon-γ activation sequence (GAS) in the promoter of the iNOS gene and activates 
its expression (Gao et al, 1997). The iNOS gene expression can also be induced without 
transcription activators binding to the GAS site, but the amount of iNOS and the 
subsequent NO produced is significantly lower (Gao et al, 1997). 
Both lipopolysaccharide (LPS) and IFN-γ induce iNOS expression in the murine 
macrophage cell line RAW264.7, of which the IFN-γ induced JAK/STAT signaling 
pathway is of particular importance, since the macrophages start mediating 
inflammatory signals when activated (Guo et al, 2007). NO production has been largely 
studied in rodent macrophages and it has been discovered to play an important role as 
a cytotoxic effector molecule (Kröncke et al, 1998). These results have, however, not 
been observed in human macrophages even if they express iNOS. Human diseases 
with chronic inflammation, i.e. rheumatoid arthritis (RA) and multiple sclerosis (MS) 
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have been associated with elevated iNOS expression (Kröncke et al, 1998) and the 
iNOS protein has also been found in post-mortem brain samples from patients with 
Alzheimer´s and Parkinson´s disease. Whether elevated iNOS expression is a primary 
or a secondary cause for the diseases has, however, not been elucidated (Kröncke et 
al, 1998). 
 RNA interference as a technique for in vitro models 1.5.
In vitro disease models are beneficial and convenient tools in medical science if patient 
samples are not available. They are of particular importance if biochemical 
mechanisms are not understood (Gartler et al, 1962) or the disease is of multigenic 
origin, i.e. many cancer types. Simplification of the macroenvironment, enabling the 
studies to be conducted in a controlled fashion, is the key for in vitro studies, but they 
do, however, never completely substitute in vivo models, thus can assumptions of 
disease mechanisms not be made solely based on them (Black, 1976). 
1.5.1. RNA interference 
RNA interference (RNAi) is a powerful and specific post-transcriptional gene regulation 
mechanism, which utilizes double-stranded RNA (dsRNA) in silencing the expression of 
a specific gene by inhibiting protein translation (Pecot et al, 2011). RNAi pathways are 
conserved in nearly all animals and plants, but the mechanism was, however, not 
discovered until the end of the 20th century. Andrew Fire and Craig C. Mello were 
rewarded the Nobel Prize in Physiology or Medicine in 2006 for their work on RNAi, 
which was published in 1998 (Fire et al, 1998).  
RNAi is widely used in biochemical and clinical research for knocking down genes, and 
latest advances have enabled its use as a therapeutic tool for treating i.e. different 
cancers. Suppression of oncogenes is challenging by traditional methods (small 
molecular inhibitors and antibodies) because the oncogenes are difficult to target 
specifically. Synthetic small interfering RNAs (siRNAs) have successfully been 
introduced to patients in vivo in more than 15 clinical trials, but these trials are 
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ongoing and the results will show the effect on disease progression within the next 
few years (Burnett & Rossi, 2012). 
1.5.2. RNA inhibitors 
The interfering RNA molecules are either endogenously transcribed during nearly all 
essential processes of the cell, such as developmental stages and viral infections, or 
exogenously introduced to the cell by viruses or by transfection. There are several 
types of repressing RNA molecules, of which microRNA (miRNA) and short interfering 
RNA (siRNA) are the best characterized. 
1.5.2.1. Endogenous RNA inhibitors 
Both miRNA and siRNA sequences are endogenously transcribed as precursors, which 
are cleaved and modified in the cell. The same locus in the genome can code for two 
different miRNAs from opposite strands, as has been reported in Drosophila 
melanogaster (Stark et al, 2008), pointing out the massive diversity and quantity of 
endogenous miRNAs. The siRNAs can arise from intergenic sequences, gene coding 
sequences, introns, and from transposable elements, as observed in Arabidopsis 
thaliana (Llave et al, 2002). 
The miRNA sequence is originally transcribed as a long stem-and-loop precursor (pri-
miRNA), which is cleaved in the nucleus by the ribonuclease (RNase) Drosha to a pre-
miRNA (Figure 7), and exported to the cytoplasm. In the cytoplasm, the pre-miRNA is 
cleaved by another RNase, Dicer, to its mature 21-23 base pair (bp) form (Burnett & 
Rossi, 2012). The siRNA sequences, which lack the stem-and-loop structure, are linear 
and are processed by Dicer only.  
Both miRNA and siRNA sequences are double-stranded, consisting of a sense- and an 
antisense strand, also known as passenger- and guide strands. The antisense strand is 
complementary to the target mRNA sequence, and the sense strand is hypothesized to 
mediate the binding to members of the argonaute (AGO) protein family (Figure 7) in 
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the catalytic site of the RNA-induced silencing complex (RISC). The RISC cleaves and 
removes the sense strand, and guides the antisense strand to the 3’ untranslated 
region (UTR) of the target mRNA sequence. If the siRNA is less than 100% 
complementary to the target sequence, the mRNA will be degraded, otherwise it gets 
cleaved (Burnett & Rossi, 2012). 
 
Figure 7.  The best characterized RNAi pathways. The endogenously transcribed miRNA 
and shRNA sequences are exported as stem-and-loop precursors from the nucleus to the 
cytoplasm, where they become modified by the RNase Dicer. Dicer modifies also the 
exogenously introduced linear siRNA sequence. All three RNA inhibitors are further bound by 
the multimer protein unit RISC, which guides the antisense-strand (red) of the RNA inhibitor to 
the target mRNA-sequence (blue), and catalyzes its proteolytic processing. Modified from 
Burnett & Rossi, 2012    
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1.5.2.2. Exogenous RNA inhibitors 
Exogenously introduced synthetic RNA inhibitors, such as exo-siRNAs and short hairpin 
RNAs (shRNAs), act similarly as the endogenously transcribed RNA inhibitors. Synthetic 
siRNA oligos are 21-26 nucleotide long double-stranded sequences with a two 
nucleotide overhang in both 3’ ends. The synthetic siRNA antisense strand is, like the 
endogenous siRNA, complementary to the mRNA sequence of the target gene, and the 
siRNA is processed and targeted in a similar way as endogenous siRNAs by Dicer and 
RISC (Burnett & Rossi, 2012; Rao et al, 2009b). The efficiency of synthetic siRNA 
inhibition is, however, hard to predict, because target gene specific features, such as 
the guanine-cytosine (GC) content, point-specific nucleotides, and specific motif 
sequences have been reported to affect RNAi efficiency (Chan et al, 2009; Takasaki, 
2010). Synthetic siRNAs have also been reported to be potential activators of the 
innate immune system in some mammalian cell lines, leading to the release of 
cytokines, such as interferons (Eberle et al, 2008; Jiang et al, 2004; Robbins et al, 2009; 
Sledz et al, 2003).  
Cell proliferation and endogenous degradation of the exo-siRNA sequences result in 
siRNA dilution and loss of RNAi (Rao et al, 2009a; Sandy et al, 2005), limiting the 
applications the method can be used for. Long-term events due to target gene 
suppression are therefore not possible to study by this method as a result of the 
transient effect of the exo-siRNA mediated RNA inhibition. 
ShRNAs are exogenously synthesized DNA-sequences, which are cloned into plasmid 
vectors and transfected into target cells (Burnett & Rossi, 2012; Rao et al, 2009b). If 
transfected as such, the shRNA is transcribed from the plasmid and creates a transient 
RNAi effect (Sandy et al, 2005). ShRNA-plasmids can, however, also be introduced to 
the genome of the target cell by transduction. Some viral methods enable the 
integration of the shRNA into the genome, thereby creating a permanent genomic 
siRNA producing sequence and a stable knockdown of the target gene. The site of 
incorporation of the shRNA sequence is, however, random, and can lead to unknown 
off-target effects (Sandy et al, 2005). Transcription of the shRNA sequence is mediated 
by the catalytic action of RNA Polymerase III (Pol III), and the transcribed sequence 
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folds into a stem-and-loop precursor, resembling the miRNA structure (Figure 7) 
(Burnett & Rossi, 2012). Long-term RNA interference, mediated by stably transduced 
shRNA, increases greatly the amount of applications that RNAi can be used for. 
1.5.3. Transfection methods 
Transfection is a molecular method used in the field of cell biology to introduce foreign 
nucleic acids, i.e. siRNAs or gene expression plasmids, into mammalian cells (Zhang et 
al, 2009). The method is used for both overexpressing and knocking down genes, 
making it an important tool for modern genetics and therapeutic research. It has 
rapidly evolved into one of the most important tools in loss-of-function mutation 
studies (Carralot et al, 2009), but it has also other important applications, i.e. in 
vaccine development. Joseph S. Pagano and Antti Vaheri described already in 1965 in 
detail the transfection of primary Rhesus monkey kidney (MK) cells with the poliovirus 
(Pagano & Vaheri, 1965), and many of these applications described are still in use. The 
transfection methods of today can roughly be divided in chemical and physical 
interference with the cell membrane, the most common being cationic lipid-based 
reagents and electroporation. The choice of method depends on the cell type and the 
nucleic acids to be transfected. All methods have off-target effects, i.e. activation of 
unwanted signaling pathways, cytotoxicity, and cell death (Jiang et al, 2004; Zhang et 
al, 2009). 
In the cationic lipid-based transfection, the uptake of extracellular nucleic acids is 
mediated by endocytosis, making it a physically gentle method. The negatively charged 
nucleic acids are first incubated with neutral and cationic lipids in order to form 
nucleic acid/liposome complexes. The uptake of the complexes by the cell membrane 
takes place by endocytosis, after which their content is released inside the cell. The 
releasing mechanism is unknown, but it is thought to be mediated by the lipids in the 
nucleic acid/liposome–complex (Zhang et al, 2009). The major drawbacks of this 
method are its rather low efficiency in hard-to-transfect cell lines and the cytotoxicity 
that the cationic lipids might create (Carralot et al, 2009). 
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Electroporation is, on the other hand, a very effective transfection method, which is 
based on predisposing the cells to an electric current. The electric current creates a 
transmembrane potential across the cell membrane (Zhang et al, 2009), changing the 
structure of the membrane and reversibly opening hydrophilic pores. The nucleic acids 
enter the cell directly through these pores without i.e. interacting with lysosomal 
compartments, thereby reducing the possibility for enzymatic degradation. The pores, 
however, open irreversibly if the transmembrane potential exceeds the tolerable 
threshold of the cell, leading to loss of membrane integrity and cell death. Due to its 
effectiveness compared to other transfection methods, electroporation is often used 
when transfecting i.e. primary cells or hard-to-transfect cell lines (Kim et al, 2008). 
Electroporation is traditionally performed in electroporation cuvettes or in thin 
capillary electrodes. 
1.5.4. Quantitative gene expression analysis by the TaqMan method 
TaqMan is a polymerase chain reaction (PCR) based method, which was originally 
created in order to simultaneously be able to amplify and quantify DNA. The method is 
applied for quantifying gene expression and chromosomal DNA deletions, and for 
detecting genetic polymorphisms (Watson & Li, 2005). The template for TaqMan is 
DNA, usually complementary DNA (cDNA) transcribed from RNA.  
Before amplifying the gene of interest, primers and probes, specific for the gene, are 
annealed with the template. The primers and probes are usually complementary to a 
cDNA region covering an exon-exon junction, which prevents the probe from binding 
to genomic DNA (gDNA) and thereby reduces the amount of false positive results 
(Proudnikov et al, 2003).  
The probe has a quencher and a fluorochrome-labeled reporter covalently attached to 
it (Figure 8), utilizing fluorescence resonance energy transfer (FRET). When the probe 
is in an intact state the quencher is physically near to the reporter, reducing the 
fluorescence that the reporter emits, and no fluorescence signal is detected. When 
amplification proceeds to the locus where the probe is bound, the Taq-polymerase 
(from the marine Thermus aquaticus) cleaves the probe by its 5’ exonuclease activity, 
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causing the reporter and quencher to dissociate. The effect of FRET diminishes, and 
the fluorescence signal from the reporter becomes detectable in a thermal cycler.  
The detected fluorescence is directly proportional to the amount of free reporter, and 
therefore to the amount of template in the logarithmic phase of the PCR cycle 
(Holland et al, 1991; Hoorfar et al, 2004; Proudnikov et al, 2003). The detected 
fluorescence signal from the gene of interest is normalized to an inner control, i.e. a 
housekeeping gene, by which bias, such as differences in template amount, is 
corrected (Holland et al, 1991). 
 
Figure 8.  The principle of the TaqMan method. Modified from Holland et al, 1991 
 
1.5.4.1.  Computational methods for TaqMan analysis 
There are different computational methods for determining the relative gene 
expression levels, of which the standard line method, the delta delta Ct (ΔΔCt) –
method, and the Pfaffl –method are well known and commonly used (Heid et al, 1996; 
Livak & Schmittgen, 2001; Pfaffl, 2001). 
The TaqMan software displays the results, with the cycle number of the PCR run on 
the X-axis and the detected fluorescence (Rn) exponentially as an arbitrary unit, on the 
Y-axis (Figure 9). The cycle, in which the detected fluorescence exceeds a linear 
baseline, is called the cycle threshold (Ct), and it is used to compute the gene 
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expression. The Ct value is dependent i.e. on DNA concentration, and therefore, is it 
not a measurement of gene expression per se (Heid et al, 1996). 
 
Figure 9.  The amplification plot obtained from the Abi Prism 7000 software after 
running triplicates of 5-fold standard samples. The cycle number on the X-axis shows at which 
cycle the captured fluorescence (Rn) on the Y-axis exceeds the cycle threshold (Ct). A higher 
concentration of template decreases the Ct for the sample. The signals below the Ct are 
emitted from primer-dimers and other artifacts, which no dot affect the final results. 
 
The standard curve – method 
 
The standard curve method is a traditional method for determining both absolute and 
relative gene expressions. A serial dilution for the gene of interest and the reference 
gene is measured on the same PCR plate as the samples. Values for the standard 
dilutions, either absolute or relative, are set. The standard curve of the gene of 
interest and the reference gene is used to calculate the target gene expression based 
on the obtained Ct values. Normalization to the reference gene and comparison of the 
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treated samples to their controls gives the relative change in gene expression (Heid et 
al, 1996). 
The standard curve method is easy to perform and it does not require complex 
mathematical formulas. However, in order to be able to analyze the results, the 
standard dilutions have to be accurately made, and the standard curve should have a 
correlation coefficient (R2) of at least 0.98 (Figure 10) (Heid et al, 1996). The standard 
dilutions of the individual genes require much space (15 wells per gene if 5-fold 
dilutions are done in triplicates) on each PCR plate, restricting the amount of space for 
actual samples. Standard curves on each plate also increase the consumption of 
reagents, and thereby the costs for the already expensive TaqMan method. Therefore, 
computational methods without using the standard line have become popular during 
the past years. 
 
The delta delta Ct (ΔΔCt) – method 
 
In the ΔΔCt –method, no standard curve is used to determine the gene expression of a 
gene of interest. The method is based on several assumptions, such as equal template 
concentrations and primer-probe efficiencies, though differences in primer-probe 
efficiencies are one of the most bias-creating factors. The primer-probe efficiencies 
can, however, be validated in advance by creating a standard line (Figure 10) for all 
primer-probes. The slope of the linear standard line represents the PCR-efficiency of 
the primer-probe set, and in order to get valid results, it should be equal (difference 
<0.1) between genes that are compared to each other (Livak & Schmittgen, 2001). 
The ΔCt value between the Ct of the gene of interest and the Ct of the reference gene 
is calculated separately for the treated and the control samples, after which the 
difference between them (ΔΔCt) is calculated, representing the change in relative gene 
expression. 
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Figure 10.  The standard line for mGapdh. In this standard line, five standard dilutions 
have been measured in triplicates, giving a correlation coefficient (R2) of 0.999. The slope of 
the standard line describes the PCR-efficiency of the primer-probe, being optimal at -3.3. The 
accuracy of the standard line increases with increased amount of standard dilutions in the 
dilution series. 
 
The Pfaffl – method 
 
The Pfaffl –method is very similar to the ΔΔCt –method. The biases affecting the Ct 
values of the samples, such as differences in template amount and the efficiency of 
the primer-probe sets, are, however, corrected when using this method (Pfaffl, 2001). 
Contrary to the ΔΔCt –method, the ΔCt values for each gene are calculated by 
subtracting the Ct value of the treated sample from the Ct value of the control sample. 
The sample specific efficiency, E target gene, is achieved by calculating the primer-probe 
specific efficiency (E) to the power of the previously obtained ΔCt value. The primer-
probe specific efficiency is determined based on the slope of its standard line. The 
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relative gene expression is finally obtained by normalizing the sample specific 
efficiency of the target gene to the sample specific efficiency of its reference gene.  
The full formula for the Pfaffl –method is shown in Equation 1. 
 
                          
 
                                                              
                                                                    
 
 
Equation 1. The Pfaffl – method takes into account the sample specific Ct and the 
efficiency of the primer-probes before normalization is done. 
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2. AIMS OF THE STUDY 
There were two aims of this study: 
 
 To create an in vitro disease model of EPM1 in two cell lines by knocking down 
cystatin B (CSTB) mRNA utilizing RNAi gene silencing technique. The models are 
exploited in the future when the physiological functions of CSTB and the 
pathophysiological consequences of CSTB deficiency are studied.  
 To study the interferon regulated JAK/STAT signaling pathway in the cystatin B 
knockdown cells, which was downregulated in primary microglia of Cstb-/- mice, as 
revealed by a previously performed gene expression profiling. 
 
Figure 11. Type I interferon-regulated Janus kinase (JAK)/Signal transducer and 
activator of transcription (STAT) –signaling pathway. A previously performed gene expression 
profiling revealed a downregulation in several members (green) of the pathway. The original 
network was generated through the use of IPA (Ingenuity Systems, www.ingenuity.com) and 
modified accordingly.  
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3. MATERIALS AND METHODS 
 Cell lines 3.1.
3.1.1. Cell origin and culturing conditions 
The human cervical adenocarcinoma cell line HeLa was purchased from ATCC-LGC 
(Manassas, VA, USA) and cultured in 1x Dulbecco´s Modified Eagle Medium (DMEM) 
(Lonza, Basel, Switzerland) with 1x glutamine (GlutaMAX, GIBCO, Life Technologies, 
Carlsbad, CA, USA), 1x Penicillin Streptomycin (PenStrep) (Invitrogen, Life 
Technologies, Carlsbad, CA, USA), and 10% Fetal Bovine Serum (FBS) (Biowest, Nuaillé, 
France). HeLa cells were cultured on Ø10 cm cell dishes (Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA). 
The murine macrophage cell line RAW264.7 was a kind gift from professor Heikki 
Rauvala, University of Helsinki (Helsinki, Finland) and cultured in 1x Roswell Park 
Memorial Institute (RPMI) 1640 medium (GIBCO, Life Technologies, Carlsbad, CA, USA) 
with 1x glutamine, 1x PenStrep, and 10% FBS. RAW264.7 cells were cultured in T-75 
cell flasks (Thermo Fisher Scientific, Waltham, MA, USA). 
3.1.2. Passaging of cells 
HeLa and RAW264.7 cells were washed twice with pre-warmed (37°C) 0.01 M (1x) 
phosphate buffered saline (PBS) (Liuoslaboratorio, Biomedicum, Helsinki, Finland) (see 
appendix), after which they were dissociated from the culture dish by trypsinization or 
scraping. One milliliter room temperature warm trypsin (TrypLETM Express, GIBCO, Life 
Technologies, Carlsbad, CA, USA) was added to the HeLa cells and they were incubated 
for 2 minutes in 37°C. Trypsinization was inhibited by adding 2 ml pre-warmed FBS 
containing growth media to the culture dish. The cells were collected in a 15 ml falcon 
tube (Thermo Fisher Scientific, Waltham, MA, USA) and pelleted by centrifugation at 
1000 g (Megafuge 1.0, Heraeus Instruments GmbH, Hanau, Germany) for 5 min at 
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room temperature. The supernatant was discarded and the pellet was resuspended in 
growth media. The RAW264.7 cells were detached from the culture dish by scraping 
them into 1 ml 1x PBS, after which they were pelleted and resuspended in growth 
medium.  
The HeLa and RAW264.7 cells were plated in a 1:2 – 1:6 ratio in a total volume of 5 and 
12 ml growth media, respectively. The cells were cultured at 37°C, 5% CO2 for one 
month or until fifteen passages had been exceeded. The cells were further passaged 
when they reached a confluency of 70-80%. 
 Transfection 3.2.
Transfection of plasmid constructs and siRNAs into the HeLa and RAW264.7 cells was 
done by electroporation (Neon transfection system, Invitrogen, Life Technologies, 
Carlsbad, CA, USA) with provided transfection reagents. The transfections were done 
following the manufacturer’s protocol described below. 
HeLa cells were co-transfected with one out of four different siRNAs against human 
CSTB mRNA (Table 3) and a plasmid expressing the autofluorescent Green Fluorescent 
Protein (GFP) (pEGFP-F, Clontech, Mountain View, CA, USA). A mitogen activated 
protein kinase 1 (MAPK1) -siRNA was used as a positive control and a nonsense siRNA 
(Neg-siRNA), complementary to no known mRNA sequence, was used as a negative 
control for RNA inhibition in HeLa cells. 
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Table 3.  siRNAs used for RNA inhibition in HeLa and RAW264.7 cells. The sense 
sequence is identical to the mRNA sequence transcribed from the gene. 
 
siRNA Sense-Sequence (5’ – 3’) Manufacturer 
Hs_CSTB_2 FlexiTube siRNA (SI00355936) CAAGAAGTTCCCTGTGTTTAA Qiagen, Venlo, Holland 
Hs_CSTB_4 FlexiTube siRNA (SI00355950) TCCAATCTCTCCCTCATGAAA Qiagen, Venlo, Holland 
Hs_CSTB_6 FlexiTube siRNA (SI03177377) CAGGTGAGGTCCCAGCTTGAA Qiagen, Venlo, Holland 
Hs_CSTB_7 FlexiTube siRNA (SI04337375) CAAGCCCTTGACCTTATCTAA Qiagen, Venlo, Holland 
Mm/Hs_MAPK1 control siRNA (1022564) CAGAGCUUUGGAGUCAGCATTTT Qiagen, Venlo, Holland 
AllStars Negative Control siRNA (1027280) Proprietary Qiagen, Venlo, Holland 
Mm_Cstb_1 FlexiTube siRNA (SI00961555) CCCAGCTTGAATCGAAAGAAA Qiagen, Venlo, Holland 
Mm_Gapd_3 FlexiTube siRNA 
(SI01009393) 
AAAUCCGUUCACACCGACCTT Qiagen, Venlo, Holland 
 
RAW264.7 cells were transfected with a mouse Cstb-siRNA, the negative control 
siRNA, and a siRNA against the mouse glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh) mRNA sequence as positive control. The MAPK1-siRNA used in HeLa cells was 
not used in the RAW264.7 cells as positive control, since the Mapk1 gene is involved in 
inflammatory pathways mediated by macrophages. All sense sequences of the siRNAs 
were aligned to known mRNA sequences by using the BLAST tool 
(http://blast.ncbi.nlm.nih.gov). 
The siRNAs, used for RAW264.7 cell transfections, were labeled by the manufacturer 
with an AlexaFluor-647 fluorochrome in their 3’ –end. The fluorochrome enabled the 
transfection efficiency to be monitored by immunofluorescence (IF) microscopy 
analysis, without performing immunofluorescence stainings of the mouse CSTB 
protein, against which a proper antibody does not exist. The transfected siRNAs and 
plasmids are shown in Tables 4 and 5. 
Mock-transfected cells, which were electroporated without siRNA or plasmid 
transfection, were used as control to detect off-target effects of the transfection 
method. 
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Table 4.  Plasmids and siRNAs transfected to HeLa cells 
 
Plasmid + siRNA Purpose 
pEGFP + CSTB_2 siRNA Knockdown of CSTB 
pEGFP + CSTB_4 siRNA Knockdown of CSTB 
pEGFP + CSTB_6 siRNA Knockdown of CSTB 
pEGFP + CSTB_7 siRNA Knockdown of CSTB 
pEGFP + MAPK1 siRNA Positive control, knockdown of MAPK1 
pEGFP + Nonsense siRNA Negative control 
 
 
Table 5.  siRNAs transfected to RAW264.7 cells 
 
siRNA Purpose 
Cstb-siRNA Knockdown of Cstb 
Gapdh-siRNA Positive control, knockdown of Gapdh 
Neg-siRNA Negative control 
Mock-transfected cells  Electroporation control 
Untreated cells  Control 
 
For transfections, 7.7 x105 HeLa or 5.0 x106 RAW264.7 cells were used per reaction. 
The HeLa cells were dissociated by trypsinization and the RAW264.7 cells by scraping. 
The cell amount, mean size, and viability were determined (Cellometer Auto T4, 
Nexcelom Bioscience, Lawrence, MA, USA), and the cells were washed twice with pre-
warmed 1x PBS and centrifuged at 850 g for 5 min at room temperature.  
The HeLa cell pellets were carefully resuspended in 90 µl buffer R, provided in the 
transfection kit. The volumes were set to 100 μl by adding 5 μl pEGFP [1.35 μg/μl] and 
5 μl siRNA [50 μM] in nuclease-free water to each tube. The cell suspensions were 
mixed before transfection by pipetting them up-and-down avoiding air bubbles. One 
hundred microliters of cell suspension were taken up in the transfection pipette tip 
and the tip was placed in the transfection pipette station with buffer E2.  
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The RAW264.7 cell pellets were resuspended into 90 μl buffer R, after which 10 μl 
siRNA [100 μM] in nuclease-free water was added into a final volume of 100 μl. Cell 
preparations were done in a similar way as with HeLa cells.  
The electroporation parameters are shown in Table 6. 
 
Table 6.  Parameters used for electroporation of HeLa and RAW264.7 cells 
 
 
 
 
Electroporated HeLa cells were resuspended in 5 ml pre-warmed transfection media 
(see appendix) and plated on Ø 6 cm cell dishes (7.7 x105 cells) and on UV-treated Ø 13 
mm cover slips (VWR international, Radnor, PA, USA) (7.7 x104 cells) in 12-well cell 
dishes (Thermo Scientific, Waltham, MA, USA).  
RAW264.7 cells were resuspended in 6 ml transfection media, and plated on Ø 6 cm 
cell dishes (3.3 x106 cells), in T-75 cell culture flasks (6.6 x106 cells) and on UV-treated 
Ø 13 mm cover slips (2.5 x105 cells) in 12-well cell dishes.  
The transfected amounts plasmid and siRNA, and the number of cells per 100 μl 
reaction are shown in Table 7. 
 
Table 7.  The amount of cells, plasmid and siRNA per reaction 
 
Cell type Amount of cells Plasmid (μg) siRNA (μM) 
HeLa 7.7 x105 5.7 (pEGFP) 2.5 
RAW264.7 5.0 x106 - 10 
 
All cells were incubated at 37°C in 5% CO2. 
HeLa cells were collected 48 hours post-transfection, and RAW264.7 cells were 
collected at time points 12, 24, 36, 48, 60, 72 and 96 hours post-transfection. 
Cell type Voltage Pulse width (ms) Amount of pulses 
RAW264.7 1680 20 1 
HeLa 1005 35 2 
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 Total RNA preparation 3.3.
Total RNA was extracted from transfected and control RAW264.7 cells from Ø 6 cm 
cell dishes, plated with 3.3 x106 cells, using an RNase Plus Mini Kit (Qiagen, Venlo, 
Holland) according to the manufacturer´s protocol described below. All steps of the 
extraction protocol were done at room temperature with reagents supplied by the kit. 
The cells were washed twice with pre-warmed 1x PBS and lysed with 1 ml 0.01% 2-
mercaptoethanol (Sigma Aldrich, St. Louis, MO, USA)/buffer RLT plus. The cells were 
harvested and homogenized by 30 strokes with an RNase-free 21 G needle (Yamaguchi 
Medical Instruments Co. Ltd, Osaka, Japan) attached to a 1 ml syringe (BD Plastipak, 
Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The cell lysate was pipetted 
into a gDNA eliminator spin column and centrifuged (Microcentrifuge 5415D, 
Eppendorf, Hamburg, Germany) at 10 000 rpm for 30 seconds. The flow through was 
mixed with an equal amount of 70% ethanol (EtOH) (ETAX, Altia, Helsinki, Finland) and 
centrifuged in 700 μl aliquots through an RNase spin column at 10 000 rpm for 15 
seconds. The RNA was washed with 700 μl buffer RW1, followed by centrifugation at 
10 000 rpm for 15 seconds.  
For RAW264.7 cells transfected with the Gapdh-siRNA, an additional DNase treatment 
was done by using a compatible RNase free DNase set (Qiagen, Venlo, Holland). After 
loading the RNA to the RNase spin column, the column was washed with 350 μl buffer 
RW1. DNase (1500 Kunitz units), diluted in nuclease-free water, was mixed 1:7 with 
buffer RDD, which was included in the RNase free DNase set, and loaded in the RNase 
spin column. An incubation period of 15 minutes at room temperature followed, after 
which an additional 350 μl of buffer RW1 was used for washing the column.  
All columns were washed twice with 500 μl buffer RPE:EtOH (1:4), followed by 
centrifugations at 10 000 rpm for 15 seconds and two minutes. The spin columns were 
dried by centrifugation in 13 200 rpm for one minute. RNA was eluted from the spin 
columns with 30 μl RNase-free water by centrifugation at 10 000 rpm for 30 seconds.  
The RNA concentrations and the purity of the samples were measured 
spectrophotometrically (Nanodrop 1000, Thermo Scientific, Waltham, MA, USA) 
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against nuclease-free water, and the samples were diluted in nuclease-free water to a 
final concentration of 1 μg/μl. 
RNA samples were stored at -80°C. 
 Reverse transcription of RNA to cDNA and verification of reverse 3.4.
transcription by the S15 gene polymerase chain reaction 
Total RNA was transcribed to cDNA using the iScript kit (Bio-Rad, Hercules, CA, USA). 
The reactions were prepared in 0.2 ml PCR-tubes (StarPCR tubes, Starlab Group, 
Merenschwand, Switzerland) on ice using 1 μl RNA [1 μg/μl] as template, after which 
19 μl reverse transcriptase (RT) reaction mix (Table 8) was added. A reaction without 
template was used as a negative control. 
RNA was transcribed to cDNA using the PCR program in Table 9.  
 
Table 8.  Reaction mix for cDNA synthesis 
 
 
 
Table 9.  Reverse transcription PCR program 
 
 
 
 
 
Reagent 
Reverse transcription 
reaction (μl) 
Negative control 
reaction (μl) 
RNA template [1 μg/μl] 1 - 
5x iScript reaction mix 4 4 
Nuclease-free water 14 15 
iScript reverse transcriptase enzyme 1 1 
Total volume 20 20 
Temperature (°C) Time (min.) 
25 5 
42 30 
85 5 
4 ∞ 
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Successful cDNA synthesis and the absence of genomic DNA were confirmed by 
amplification of the ribosomal subunit S15 gene from the cDNA and the RNA. 
The protocol for the S15 gene PCR reaction and the amplification program are shown 
in Table 10 and 11, respectively, and the primer sequences for the S15 gene PCR are 
seen in the appendix. 
 
Table 10.  S15 PCR reaction mix 
 
Reagent μl 
Template 1 
10x Standard reaction buffer (Biotools, Jupiter, FL, USA) 2 
dNTP [10 μM] (F-560, Finnzymes, Espoo, Finland) 0.4 
S15 forward primer [20 μM] (Sigma Aldrich, St. Louis, MO, 
USA) 0.5 
S15 reverse primer [20 μM] (Sigma Aldrich, St. Louis, MO, 
USA) 0.5 
DNA-polymerase (1 U/μl) (Biotools, Jupiter, FL, USA)  0.6 
Nuclease-free water 15 
Total volume 20 
 
 
Table 11.  S15 amplification program 
 
Temperature (°C) Time (min.)  
94 5  
94 0.5  
55 0.5 30 cycles 
72 0.5  
72 10  
 
After amplification, 4 μl of 6x loading buffer (Orange Dye, Fermentas, Thermo 
Scientific, Waltham, MA, USA) were added to the PCR products and they were 
electrophoresed in 0.5x Tris/borate/EDTA (TBE) (Thermo Scientific, Waltham, MA, 
USA) for 40 minutes in 120 V in a 1.5% agarose (BIO-41025, Biotop Oy, Turku, 
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Finland)/TBE gel  containing the DNA binding fluorescent stain Midori Green (Nippon 
Genetics Europe, Dueren, Germany). Four microliters of DNA-ladder (100 bp+500 bp, 
0.05 μg/μl) (O’RangeRuler, Fermentas, Thermo Scientific, Waltham, MA, USA) was 
used as a marker for DNA bands of different sizes and the PCR products were 
visualized by UV-light (AlphaImager, Protein Simple, Santa Clara, CA, USA). 
 Quantitative real-time PCR 3.5.
Gene expression levels from the Cstb-siRNA, Neg-siRNA, and Gapdh-siRNA transfected 
cells, and the mock-transfected control cells, were measured by quantitative real-time 
PCR (qRT-PCR) using the TaqMan method, according to the protocol by Applied 
Biosystems (Foster City, CA, USA) 
(https://tools.invitrogen.com/content/sfs/manuals/cms_041280.pdf).  
The expression levels of target genes were compared to the expression level of the 
general transcription factor TATA-box binding protein gene (Tbp), which was used as 
an endogenous control. Two or three experimental runs were performed for all 
samples. Reactions were prepared in duplicates, and expression values having a 
standard deviation of ± 0.2 were excluded. The mRNA expression levels were 
calculated using the Pfaffl method (Pfaffl, 2001). 
The TaqMan primer-probes (Table 12) were pre-designed by the manufacturer and 
they were intron-spanning, with the exception of the Gapdh primer-probe. Cstb-siRNA 
and Neg-siRNA transfected cells were measured for the gene expression levels of Cstb, 
Stat1, Stat2, Irf9, and Tbp, and Gapdh-siRNA transfected cells were measured for Cstb, 
Stat1, Tbp, and Gapdh. All genes listed in Table 12 were measured for the expression 
levels of the mock-transfected cells. 
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Table 12.  Primer-probes used in TaqMan-qRT-PCR 
 
 
The cDNA was diluted 1:2 with nuclease-free water, and 2 μl of the dilution was used 
per PCR-reaction of 20 μl containing reagents seen in Table 13. 
 
Table 13.  Reaction mix for TaqMan qRT-PCR 
 
 
 
 
 
 
 
The reactions were performed in a 96-well plate (MicroAmp, Applied Biosystems, 
Foster City, CA, USA), and the qRT-PCR program was carried out with the ABI PRISM 
7000 Sequence detection system (Applied Biosystems, Foster City, CA, USA). The 
program for TaqMan qRT-PCR is seen Table 14. 
 
 
Probe ID Manufacturer 
Cystatin B (Cstb) Mm00432769_m1 Applied Biosystems, Foster City, 
CA, USA 
Signal transducer and activator 
of transcription 1 (Stat1) 
Mm00439531_m1 Applied Biosystems, Foster City, 
CA, USA 
Signal transducer and activator 
of transcription 2 (Stat2) 
Mm00490880_m1 Applied Biosystems, Foster City, 
CA, USA 
Interferon regulatory factor 9 
(Irf9) 
Mm00492679_m1 Applied Biosystems, Foster City, 
CA, USA 
TATA box binding protein (Tbp) Mm00446973_m1 Applied Biosystems, Foster City, 
CA, USA 
Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) 
Mm99999915_g1 Applied Biosystems, Foster City, 
CA, USA 
Reagent μl 
cDNA template 2 
2x TaqMan Universal PCR Master Mix (Roche Applied 
Science, Penzberg, Germany) 10 
TaqMan primer-probe (Table 12) 1 
Nuclease-free water 7 
Total volume 20 
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Table 14. PCR program for TaqMan qRT-PCR 
 
Temperature (°C) Time (min.) 
 50 2 
 95 10 
 95 0:15 40 cycles 
60 1  
 
The results were analyzed with the ABI PRISM 7000 system software (Applied 
Biosystems, Foster City, CA, USA), and MS Excel (Microsoft Corporation, Redmond, 
WA, USA). 
 Fixation of cells with phosphate-buffered 4% paraformaldehyde 3.6.
(PFA) 
HeLa and RAW264.7 cells plated on coverslips, 7.7 x104 and 2.5 x105 respectively, were 
fixed with 4% paraformaldehyde (PFA) (PFA/PBS) (Liuoslaboratorio, Biomedicum, 
Helsinki, Finland). The coverslips were carefully moved to a sterile 12-well cell dish and 
the cells were washed twice with 1 ml pre-warmed 1x PBS. The cells were fixed for 15 
minutes at room temperature with 1 ml 4% PFA. The PFA was removed, and the fixed 
cells were washed twice with 1x PBS, after which they were stored in 1x PBS at +4°C 
protected from light. 
 Antibodies and indirect immunofluorescence stainings 3.7.
All steps comprising the indirect immunofluorescence (IF) stainings were performed 
with the samples protected from light in order to inhibit bleaching of the 
fluorochrome labeled siRNAs, which were transfected to RAW264.7 cells. 
The fixed cells were rinsed three times with 1x PBS, and the cell membranes were 
permeabilized with 0.1% Triton X-100 (Sigma Aldrich, St. Louis, MO, USA)/1x PBS for 10 
min at room temperature. RAW264.7 cells were incubated with 0.5% Bovine Serum 
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Albumin Fraction V (BSA) (Roche Applied Science, Penzberg, Germany)/1x PBS and 
HeLa cells with 10% FBS/1x PBS for one hour at room temperature in slow shaking 
(See-saw rocker SSL4, Bibby Scientific, Staffordshire, UK) to prevent unspecific binding 
of antibodies.  
The primary antibodies were diluted (Table 15) in cold 0.5% BSA/1x PBS and 1% 
FBS/1x PBS for RAW264.7 and HeLa cells, respectively. Thirty microliter primary 
antibody solution was incubated with the cells for one hour at room temperature. The 
diluent without antibody was used as a negative primary antibody control. The cells 
were washed three times for 15 minutes with the diluent. 
 
Table 15.  Primary antibodies used in indirect immunofluorescence stainings 
 
Antibody Dilution Host Manufacturer 
STAT1 1:200 rabbit Santa Cruz Biotechnology, Dallas, TX, 
USA 
NOS2 (iNOS) 1:200 rabbit Santa Cruz Biotechnology, Dallas, TX, 
USA 
GFP 1:100 rabbit Sigma Aldrich, St. Louis, MO, USA 
 
An Alexa Fluor-488 labeled secondary antibody (donkey anti-rabbit) (Invitrogen, Life 
Technologies, Carlsbad, CA, USA) was diluted in cold 0.5% BSA/1x PBS or in 1% FBS/1x 
PBS, and 30 μl of the dilution was incubated with the cells for 30 minutes at room 
temperature. The diluent without antibody was used as a negative secondary antibody 
control.  
The cells were washed three times for 15 minutes, once with the diluent and twice 
with 1x PBS at room temperature. 
The DNA of the cells was stained by incubating the cells for five minutes in Hoechst 
(Molecular Probes, Life Technologies, Carlsbad, CA, USA), diluted 1:5000 in 1x PBS, in 
slow shaking at room temperature. The excess stain was washed off by rinsing the 
cells three times with 1x PBS. 
Excess salts were washed off the coverslips by soaking them in double distilled sterile 
water (ddsH2O) for 30 seconds. A drop of mounting media (Fluoromount, Sigma 
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Aldrich, St. Louis, MO, USA) was placed on a sterile microscope slide (Thermo 
Scientific, Waltham, MA, USA) and the coverslips were placed cell-side down on the 
drop. The samples were dried overnight at room temperature protected from light, 
after which they were stored at 8°C. 
Epifluorescence (Zeiss AxioImager Z1, Carl Zeiss AG, Oberkochen, Germany) and 
confocal (Zeiss LSM 710, Carl Zeiss AG, Oberkochen, Germany) microscopy was used 
for visualizing the bound antibodies. 
 Protein extraction 3.8.
Total protein was extracted from transfected HeLa and RAW264.7 cells (7.7 x105 and 
6.6 x106 cells, respectively) growing on Ø 6 cm cell dishes and in T-75 cell culture 
flasks. Upon harvesting protein lysates from RAW264.7 cells at various time points, 
200 μl growth media was collected from the cell culture dishes and stored at -80°C for 
further analysis. 
The cell culture dishes were placed on ice and cells were washed twice with ice cold 1x 
PBS. Five hundred microliters of cold cell lysis buffer (see appendix) was added to the 
HeLa cells, and they were scraped off with a pre-cooled cell scraper and pipetted into 
a cooled eppendorf tube and kept on ice. Two hundred microliters cell lysis buffer was 
used in a similar way for RAW264.7 cells. 
The cell suspensions were mixed by vortexing (Vortex-Genie2, Scientific Industries, 
Bohemia, NY, USA) three times for two seconds, after which the tubes were slowly 
rotated (Labover, type 460251) for five minutes at 8°C. The cells were centrifuged 
(Microcentrifuge 5415D, Eppendorf, Hamburg, Germany) at 10 000 rpm for 10 min at 
8°C. The supernatant containing the soluble proteins was separated from the pelleted 
cell debris and transferred into a new pre-cooled eppendorf tube and stored at -20°C. 
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 Detection of nitrite by the Griess test 3.9.
Organic nitrite compounds were detected from the growth media of transfected 
RAW264.7 cells. Frozen growth media was thawn on ice, and cell debris was pelleted 
at 10 000 rpm for 10 minutes at +8°C.  
Fifty microliters of growth media, collected at each examined time point, was pipetted 
as duplicates into a 96-well dish (Midland Scientific, Omaha, NE, USA) on ice. Nitrite 
(NO2
-) standards (0, 2.5, 5, 10, 15, 20, 40, 60, 80, 100 μM), diluted in fresh growth 
media, were pipetted as duplicates in the same 96-well dish. 
Fifty microliter Griess reagent (Sigma Aldrich, St. Louis, MO, USA) was carefully mixed 
in each sample and after an incubation period of 15 minutes at room temperature, the 
absorbance at 510 nm was measured (VICTOR2™, PerkinElmer, Waltham, MA, USA) 
against the NO2
- standard dilutions. 
 Measurement of protein concentration by the Bradford method 3.10.
The protein lysates were diluted 1:5 with pre-cooled ddsH2O, and 10 μl of the dilutions 
were carefully pipetted as triplicates into a 96-well dish (Midland Scientific, Omaha, 
NE, USA) on ice. BSA standard dilutions (0, 125, 250, 500, 750, 1000 ng/μl) were 
pipetted as duplicates in the same 96-well dish. 
Two hundred microliters of Bradford dye (Bio-Rad Protein Assay, Bio-Rad, Hercules, 
CA, USA), diluted 1:5 with water, was added into each sample, which were mixed 
carefully avoiding bubbles. Each sample was incubated for five minutes at room 
temperature and the protein concentrations were measured spectrophotometrically 
(Labsystems multiskan MS, Helsinki, Finland) against the BSA standard dilutions.  
Replicates with variation more than 10% were excluded, and the mean value was 
determined based on the remaining replicates. 
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  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 3.11.
Protein samples for SDS-PAGE were prepared on ice by diluting the protein lysates in 
pre-cooled ddsH2O to 7.5 or 10 μg proteins per sample of HeLa or RAW264.7 cells. A 
5x Laemmli buffer (see appendix) containing the reducing agent 2-mercaptoethanol 
(Sigma Aldrich, St. Louis, MO, USA) (2:1) was added to the diluted samples. The 
samples were heated (ThermoCell CHB202, Hangzhou Bioer Technology Co, Hangzhou, 
China) at +95°C for 5 min, after which they were quickly centrifuged (Spectrafuge 24D, 
Labnet International Inc., Woodbridge, NJ, USA).  
Proteins were separated in 1x SDS-PAGE running buffer (Liuoslaboratorio, 
Biomedicum, Helsinki, Finland) (see appendix) in pre-casted Tris-Glycine gels (Mini-
PROTEAN TGX, 12% and any kD, Bio-Rad, Hercules, CA, USA) using a pre-stained 
protein marker (SM1811, Fermentas, Thermo Scientific, Waltham, MA, USA for HeLa 
cells, and 161-0373, Bio-Rad, Hercules, CA, USA for RAW264.7 cells) as size marker. 
The separation was conducted using the following conditions; 90 V for 30 min, 110 V 
for 10 min and 130 V for 30 min (Bio-Rad PowerPac 1000, Bio-Rad, Hercules, CA, USA). 
 Western blot analysis 3.12.
Proteins separated in the SDS-PAGE gel were electroblotted to a polyvinylidene 
difluoride (PVDF) membrane (GE Healthcare, Little Chalfont, UK). The PVDF membrane 
was activated with 100% methanol (MeOH) (Thermo Fisher Scientific, Waltham, MA, 
USA), after which it was rinsed in ddsH2O for five minutes and equilibrated in 1x Tris-
glycine transfer buffer (Liuoslaboratorio, Biomedicum, Helsinki, Finland) (see 
appendix) containing 20% MeOH.  
The blotting system (Bio-Rad, Hercules, CA, USA) was assembled by placing the SDS-
PAGE gel and the membrane against each other and placing two chromatography 
papers (Whatman, Grade 3MM Chr, GE Healthcare, Little Chalfont, UK) and a foam pad 
on each side. Air bubbles were eliminated and the assembled system was placed in a 
gel holder cassette. Proteins were transferred in ice cold 1x transfer buffer containing 
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20% MeOH under moderate stirring for 35 minutes in 0.35 A (Bio-Rad PowerPac 200, 
Bio-Rad, Hercules, CA, USA) at +8°C. 
Successful transfer was confirmed by staining the membrane with Ponceau S (see 
appendix) for one minute, followed by rinsing it with ultrapure Milli-Q water (MQ-H2O) 
and activation of the membrane with 100% MeOH, which revealed the transferred 
protein bands. The SDS-PAGE gel was stained after transfer with Bio-safe Coomassie 
stain (Bio-Rad, Hercules, CA, USA) to detect remaining proteins.  
The PVDF membrane was rinsed in PBST (PBS/0.1% Tween-20 (Thermo Fisher 
Scientific, Waltham, MA, USA)) for five minutes in moderate shaking and blocked for 
unspecific binding of antibodies with 5% BSA/PBST for one hour at room temperature. 
Primary antibodies were diluted (Table 16) in 5% BSA/PBST and the solution was 
added to the membrane and incubated overnight at 8°C. 
 
Table 16.  Primary antibodies used in Western Blot analysis 
 
Antibody Dilution Host Manufacturer 
CSTB (mouse) 1:1000 rabbit Biogenesis, AbD Serotec, Kidlington, 
UK 
STAT1 1:500 rabbit Santa Cruz Biotechnology, Dallas, TX, 
USA 
STAT2 1:1000 rabbit Merck Millipore, Billerica, MA, USA 
NOS2 (iNOS) 1:2000 rabbit Santa Cruz Biotechnology, Dallas, TX, 
USA 
ERK2 (MAPK1) 1:400 mouse Santa Cruz Biotechnology, Dallas, TX, 
USA 
Beta-tubulin 1:5000 mouse Sigma Aldrich, St. Louis, MO, USA 
2E7 (human CSTB) 1:1000 mouse Kind gift from Eckehard Weber, 
Germany  
 
The membrane was washed six times for 10 minutes with PBST at room temperature. 
For HeLa cells, a horseradish peroxidase (HRP)-conjugated secondary antibody (Table 
17) was diluted in 5% BSA/PBST, and for RAW264.7 cells, a fluorochrome conjugated 
secondary antibody (Table 18) was diluted in 1% milk powder (Valio Oy, Helsinki, 
Finland)/PBST + 0.01 % SDS (Sigma Aldrich, St. Louis, MO, USA).  Secondary antibodies 
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were incubated with the membrane for one hour at room temperature in moderate 
shaking, protected from light. 
 
Table 17.  Secondary antibodies used for HeLa cells in Western Blot analysis 
 
Antibody Dilution Manufacturer 
Goat Anti-mouse/HRP 1:5000 DAKO, Glostrup, Denmark 
Swine Anti-rabbit/HRP 1:5000 DAKO, Glostrup, Denmark 
 
 
Table 18. Secondary antibodies used for RAW264.7 cells in Western Blot analysis 
 
Antibody Dilution Host Manufacturer Fluorochrome 
Anti-mouse 1:10000 Goat LI-COR Biosciences, Lincoln, NE, USA IRDye® 800CW 
Anti-rabbit 1:10000 Goat LI-COR Biosciences, Lincoln, NE, USA IRDye® 800CW 
 
The membrane, to which the HeLa cell proteins had been transferred to, was washed 
three times with PBST, 15 minutes each. The membrane was incubated for five 
minutes protected from light with a chemiluminescent substrate (Thermo Fisher 
Scientific, Waltham, MA, USA) consisting of luminol and peroxide solutions diluted in 
1x PBS (1:1:2). After the incubation period, the membrane was placed in a cassette 
(Trimax T16, 3M, St. Paul, MN, USA) between two plastic covers and air bubbles were 
removed. Proteins were detected by exposing the chemiluminescent membrane to an 
X-ray film (Kodak BioMax, Sigma Aldrich, St. Louis, MO, USA), and quantified with the 
software ImageJ (National Institutes of Health, Bethesda, MD, USA) 
(http://rsbweb.nih.gov/ij/). 
The membrane,  with proteins from RAW264.7 cells, was washed six times with PBST, 
10 minutes each, after which it was quickly rinsed with 1x PBS. Bound antibodies were 
detected by scanning the membrane with the Odyssey Infrared Imaging system (LI-
COR Biosciences, Lincoln, NE, USA), and quantified with the Odyssey Software (LI-COR 
Biosciences, Lincoln, NE, USA). 
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 Statistical analyses 3.13.
All results obtained from qRT-PCR, Western blot, and immunofluorescence analyses 
were normalized against mock-transfected cells, unless otherwise mentioned. 
Probability (p) was calculated using Student’s two-tailed heteroscedastic t-test with 
values obtained from the Neg-siRNA transfected cells as the control data set. P-values 
< 0.05 were considered statistically significant. 
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4. RESULTS 
 Cystatin B knockdown in HeLa cells 4.1.
4.1.1. Co-transfection of pEGFP and CSTB-siRNA to HeLa cells 
RNA-inhibition was optimized in the human cervical carcinoma cell line, HeLa. 
Electroporation was chosen as transfection method, and in order to verify its success, 
a plasmid encoding the autofluorescent green fluorescent protein (pEGFP) was co-
transfected with the CSTB-siRNA. 
Immunofluorescence stainings with an anti-GFP antibody were carried out on cells, 
which had been fixed at 48 hours post-transfection. The expression of GFP showed 
which HeLa cells had been transfected (Figure 12). Morphological changes of HeLa 
cells due to transfection were not observed. 
 
Figure 12. Anti-green fluorescent protein (GFP) (green) stained HeLa cells. Expression of 
GFP, proportional to the visualized fluorescence, shows which cells have been transfected with 
pEGFP. The nuclei of the cells are stained with Hoechst. 
Scale 50 µm. 
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4.1.2. Verification of CSTB knockdown in HeLa cells 
Human cystatin B (CSTB) knockdown by using different siRNAs was verified by Western 
blot (WB) analysis (Figure 13A), and quantified by Image J software (Figure 13B). All 
four CSTB-siRNAs downregulated the CSTB protein expression, but some siRNA specific 
differences in efficiency were observed. The CSTB-siRNA4 was most efficient, reducing 
the protein expression level down to 1% of the control cells. CSTB-siRNA1-3 knocked 
down the expression level of CSTB to 7-15%. A decrease in CSTB expression was also 
observed in the positive control cells transfected with the MAPK1-siRNA. CSTB-
knockdown did not, however, affect MAPK1-expression (Figure 13A). The obtained 
results are normalized to the values from the negative control siRNA (Neg-siRNA) 
transfected HeLa cells. 
 
Figure 13.  A. Western blot analysis of cystatin B (11 kDa) expression in HeLa cells. The 
siRNA mediated inhibition of CSTB (CSTB-siRNA1-4, lanes 3-6) was confirmed on protein level. 
Cells transfected with the positive control siRNA (MAPK1-siRNA, lane 1) and the negative 
control siRNA (Neg-siRNA, lane 2) express CSTB. MAPK1 (42 kDa) was downregulated in the 
positive control, but not in any other sample. β-tubulin (55 kDa) was used as loading control. 
The proteins are indicated on the left, and their molecular weights (kDa) on the right. B. 
Quantification of the Western blot by the ImageJ software. All CSTB-siRNAs (light blue) 
downregulated CSTB, but CSTB-siRNA4 was the most sensitive. A downregulation of CSTB was 
also observed in the MAPK1-knockdown cells (dark blue). All values are normalized to the 
values acquired from the Neg-siRNA (grey) transfected cells, and the obtained fold change is 
marked above the bars. 
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4.1.3. Effects of CSTB knockdown on STAT1, STAT2, and iNOS expression in HeLa cells 
In order to verify whether CSTB downregulation had an effect on the members of the 
JAK/STAT signaling pathway, WB analysis was performed for the proteins STAT1, 
STAT2, and iNOS. Downregulation of CSTB in HeLa cells did not change the expression 
levels of STAT1 in a substantial manner (Figure 14A and 14B), however, STAT1 
expression was increased by 2-fold in MAPK1-knockdown cells (Figure 14B). STAT2 and 
iNOS expression could not be detected by WB analysis (data not shown). 
 
Figure 14. A. Western blot analysis of STAT1 (84/91 kDa) expression in CSTB 
knockdown HeLa cells. No clear difference in STAT1 expression was observed between the 
CSTB inhibited (lanes 3-6) and the MAPK1- and Neg-siRNA transfected control cells (lanes 1-2). 
β-tubulin (55 kDa) was used as a loading control. The proteins are indicated on the left, and 
their molecular weights (kDa) on the right. B. Quantification of the Western blot with the 
ImageJ software.  Increased STAT1 expression was detected in the CSTB-siRNA1 transfected 
cells, but not in the other CSTB knockdown cells (green). MAPK1-downregulated cells (dark 
blue) had a 2-fold increase in STAT1 expression. All values are normalized to the values 
acquired from the Neg-siRNA transfected cells (grey), and the obtained fold change is marked 
above the bars. 
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 Cystatin B knockdown in RAW264.7 cells 4.2.
4.2.1. Transfection of siRNA to RAW264.7 cells 
Cstb was knocked down in the murine macrophage cell line RAW264.7. Alexa Fluor-
647 labeled siRNA molecules were used, which allowed the verification of successful 
transfection by IF microscopy. Nearly all cells were positive for the fluorochrome 
(Figure 15a), indicating a high transfection rate. Mock-transfected cells were used as 
control (Figure 15b).  
 
 
 
 
Transfected and control cells were monitored up to 96 hours post-transfection. With 
the exception of cells in two cell culturing flasks, no morphological changes were 
observed at any examined time point. The observed morphological changes in the two 
flasks were present in such cells (Neg-siRNA transfected and untreated control cells) 
which were aimed for protein extraction at the time point 60 hours. Protein lysates 
Figure 15. siRNA transfection in RAW264.7 cells was detected by immunofluorescence 
(IF) microscopy. The siRNA sequences were labeled with an Alexa Fluor-647 fluorochrome in 
their 3’-end, allowing their cellular location to be monitored by IF microscopy (a). Mock-
transfected cells do not express the fluorescent signal (b).  
Scale 20µm. 
a) b) 
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and growth media were collected from these cells as planned, and the samples were 
used for Western blot analysis and to perform the Griess test. 
4.2.2. Total RNA purity and reverse transcription of RNA to cDNA 
After total RNA extraction, RNA purity and cDNA synthesis were confirmed by 
amplification of the ribosomal subunit S15 gene, and as a template were used both 
cDNA and RNA. The presence of the S15-fragment (361 bp) in samples with cDNA as 
template confirmed that reverse transcription was successful (Figure 16). The absence 
of the fragment in reactions with RNA as template confirmed that there was no 
genomic DNA contamination in the RNA. 
 
Figure 16. Representative S15-PCR-products electrophoresed in a 1.5% agarose/TBE 
gel. Sample “a” represents a PCR product with total RNA as template and sample “b” the 
corresponding sample with cDNA as template. Genomic contamination in the “a” sample 
would result in amplification of the S15 gene, which is not detected. The S15 gene was 
amplified in the “b” samples, confirming successful reverse transcription. The diffuse bands, 
seen in “a” samples, consist of primer-dimers. 
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4.2.3. Sensitivity of Cstb downregulation 
Cstb downregulation was analyzed from Cstb-siRNA, Neg-siRNA, Gapdh-siRNA, and 
mock-transfected cells by qRT-PCR. The Cstb-siRNA sensitivity was high, seen as 
effective downregulation of Cstb mRNA (Figure 17). Downregulation of Cstb was not 
detected in the control cells, transfected with the Gapdh- or Neg-siRNA. The Gapdh-
siRNA transfected cells did not change in Cstb expression during the time points (fold 
changes between 0.9 and 1.15), but some variation in Cstb expression was observed in 
the Neg-siRNA transfected cells, particularly between the time points 36 and 96 hours 
(fold changes between 0.95 and 1.4). 
 
Figure 17. Cstb mRNA expression in siRNA transfected RAW264.7 cells at time points 
12, 36, 60, and 96 hours. The Cstb mRNA inhibition was shown to be specific to the Cstb-siRNA 
sequence (light blue), and the obtained variation between Cstb- and Neg-siRNA (grey) 
transfected cells, indicated as p-values, remained significant until the 96-hour time point. 
Some variation in Cstb mRNA expression was detected in the Neg-siRNA, but not in the Gapdh-
siRNA (dark blue) transfected control cells. The expression values were obtained from TaqMan 
using the Pflaffl –method, and the expression of Cstb mRNA was normalized to the expression 
levels of Tbp. The expression levels are shown in relation to mock-transfected cells. 
Measurements were performed three independent times, and the error bars represent the 
standard deviations (SD). P-values are marked above the bars. The + - and the – -signs at the 
lower panel indicate which siRNA the cells have, and have not been transfected with.  
 
 
56 
 
4.2.4. The kinetics of the Cstb mRNA expression 
The Cstb mRNA levels were measured from siRNA and mock-transfected cells collected 
at time points 12, 24, 36, 48, 60, 72, and 96 hours post-transfection. The expression 
levels of Cstb mRNA from Cstb-siRNA transfected cells were normalized against the 
expression levels obtained from the mock-transfected cells, and a curve describing the 
kinetics of Cstb mRNA was plotted (Figure 18). 
Cstb mRNA expression was at its minimum 12 hours post-transfection, being 
downregulated to 3% of mock-transfected cells. The expression levels of Cstb 
increased steadily after 12 hours, being 6% at 24 hours, 14% at 36 hours, 23% at 48 
hours, and 24% at 60 hours. At the 72 hour time point, the expression levels of Cstb 
mRNA had increased to 50% of the control level. At 96 hours, the transient effect of 
the siRNA on Cstb expression could not anymore be detected. 
 
Figure 18. The kinetics of Cstb mRNA expression after Cstb-siRNA transfection in 
RAW264.7 cells. The Cstb mRNA expression levels were most downregulated at the first 
measured time point, 12 hours, being 3% of control values. The mRNA expression of Cstb 
increased steadily at the following time points, increasing steeply after 60 hours. At the final 
time point, 96 hours, the mRNA expression of Cstb was reverted. The Cstb expression level is 
not done (n/d) for the time point 84 hours. The expression values were obtained from TaqMan 
using the Pfaffl –method, and the expression of Cstb was normalized to the expression levels 
of Tbp. The expression levels are shown in relation to mock-transfected cells. 
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The positive control, Gapdh-siRNA, was used in order to verify the specific and to rule 
out the unspecific changes in Cstb knockdown cells. The kinetics of Gapdh mRNA 
(Figure 19) in the Gapdh knockdown cells resemble the kinetics observed with Cstb 
mRNA (Figure 18). The expression levels of Gapdh are, similarly to Cstb mRNA, most 
downregulated at the time point 12 hours, increasing after that. Gapdh mRNA stays, 
however, downregulated for a longer time period, estimated to reach 50% of the 
expression levels of mock-transfected cells around the time point 84 hours. Similarly 
to Cstb mRNA, Gapdh mRNA starts to increase linearly in expression after the time 
point 60 hours, but with a less steep slope. 
 
Figure 19. The kinetics of Gapdh mRNA expression at different time points. The kinetics 
of Gapdh mRNA expression levels resembles the kinetics of Cstb mRNA. Gapdh mRNA is, 
however, downregulated for a longer time. The Gapdh expression level is not done (n/d) for 
the time point 84 hours. The expression levels were obtained from TaqMan using the Pfaffl –
method, and the expression of Gapdh mRNA was normalized to the expression levels of Tbp. 
The expression levels are shown in relation to mock-transfected cells. 
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4.2.5. The kinetics of the CSTB protein expression 
The CSTB protein expression was detected by WB analysis (Figure 20a). The kinetics of 
the CSTB protein had similar progression as the Cstb mRNA expression, though CSTB 
was less downregulated on protein level (Figure 20b). At the time points 12 and 24 
hours, CSTB was downregulated to 30% and 34%, respectively. The CSTB expression 
decreased at 36 and 48 hours to 23% and 22%, and it started to increase at 60 hours 
being 25%.  At 72 hours, the expression level of CSTB was 46%. At the final time point, 
96 hours, the protein was still downregulated to 53%, whereas on mRNA level, the 
expression was already reverted (Figure 18). The differential kinetics between the Cstb 
mRNA and the CSTB protein demonstrates i.a. the delay in translation to protein. 
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Figure 20. A. Western blot analysis of CSTB (11 kDa) expression in RAW264.7 cells. The 
siRNA mediated inhibition of Cstb was confirmed on protein level from samples collected at 
different time points. CSTB expression was downregulated throughout 12-96 hours, in 
particular between 36 and 60 hours. Mock-transfected cells express CSTB at all the time 
points. β-tubulin (55 kDa) was used as loading control. The proteins are indicated on the left, 
and their molecular weights (kDa) on the right. The time points are indicated above the lanes. 
B. The kinetics of CSTB protein expression after Cstb-siRNA transfection in RAW264.7 cells. 
Maximal downregulation of the CSTB protein is seen between the time points 36 and 48 
hours. By the 96 hour time point CSTB is still downregulated by almost half. Expression of CSTB 
is shown in relation to mock-transfected cells, and the obtained fold change at each time point 
is shown at the panel below the figure. The CSTB expression level is not done (n/d) for the 
time point 84 hours. Quantification of the Western blot was done using the Odyssey software. 
b) 
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4.2.6. The effect of Cstb knockdown on the ISGF3-complex members 
QRT-PCR, WB-, and IF microscopy analyses were performed in order to study the 
effects of Cstb knockdown on the expression levels of the ISFG3-complex members 
Stat1, Stat2, and Irf9. 
4.2.6.1. Signal transducer and activator of transcription 1 (Stat1) 
The Stat1 mRNA expression, measured by qRT-PCR, increased initially after Cstb-siRNA 
transfection until the time point 36 hours (Figure 21). At the time point 48 hours the 
Stat1 expression, however, decreased to the level of mock-transfected cells, and at the 
time point 60 hours, a downregulation to 65% of the control level was measured. After 
this downregulation, at the time point 72 hours, the Stat1 mRNA expression level 
increased back to its base level, and stabilized in expression at 96 hours. Only minor 
changes in Stat1 mRNA expression levels were observed in the positive control, Gapdh 
knockdown cells. In the Neg-siRNA transfected cells, the Stat1 expression varied 
somewhat and presented with similar kinetics as with the Cstb knockdown cells. 
Variation in Stat1 expression was, however, not detected in same degree as with the 
Cstb knockdown cells. 
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Figure 21.  The mouse Stat1 mRNA expression in differentially transfected RAW264.7 
cells. Stat1 mRNA expression levels were upregulated in Cstb-siRNA (green) transfected cells 
until the time point 36 hours. At the time point 48 hours, the Cstb knockdown cells had 
decreased Stat1 expression and kept decreasing until the time point 60 hours (fold change 
0.65). A brief increase in Stat1 expression was detected at the last time points (72 and 96 h). 
Variation was observed in the Neg-siRNA (grey) transfected cells similarly as in the Cstb 
knockdown cells, however, the changes were not as intense.  Changes in Stat1 expression 
were not observed in the Gapdh knockdown (dark blue) cells at any time point. The expression 
values were obtained from TaqMan using the Pflaffl –method and the expression of Stat1 was 
normalized to the expression levels of Tbp. The expression levels are shown in relation to 
mock-transfected cells. Measurements were performed three independent times, and the 
error bars represent the standard deviations (SD). P-values are marked above the bars. The + - 
and the – -signs at the lower panel indicate which siRNA the cells have, and have not been 
transfected with. 
 
The changes in STAT1 expression in the Cstb knockdown cells were verified by WB 
analysis (Figure 22). The kinetics resemble those observed on mRNA level, however, a 
slight downregulation of STAT1 was not detected until the time point 96 hours (fold 
change 0.9). 
An upregulation of STAT1 was detected at the 60 hour time point in the Neg-siRNA 
transfected cells (fold change 3.5) 
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Figure 22. A. Western blot analysis of the STAT1 protein expression in RAW264.7 cells. 
STAT1 (84/91 kDa) upregulation was detected in Cstb knockdown cells (Cstb-siRNA) at the 36 
and 48 hour time points. Neg-siRNA transfected and untreated cells presented with an 
upregulation of STAT1 at the 60 hour time point. β-tubulin (55 kDa) was used as loading 
control. The proteins are indicated on the left, and their molecular weights (kDa) on the right. 
The time points are indicated above the lanes. B. Quantification of the Western blot by the 
Odyssey software. As observed in Fig. 22a, the initial upregulation of STAT1 in Cstb 
knockdown cells (green) was reverted at the time point 60 hours, at which STAT1 decreased in 
expression. A slight downregulation in relative protein expression was detected at the time 
point 96 hours. STAT1 expression was also increased in the Neg-siRNA transfected cells (grey), 
but downregulated at 48 hours. With the exception of the time point 60 hours, the Neg-siRNA 
transfected cells express less STAT1 protein than the Cstb knockdown cells. Expression of 
STAT1 is shown in relation to mock-transfected cells. The + - and the – -signs at the lower 
panel indicate which siRNA the cells have, and have not been transfected with. 
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Downregulation of the STAT1 protein in the Cstb knockdown cells was also observed 
by IF microscopy at 96 hours (Figure 23). The cellular distribution of the STAT1 protein 
was mainly cytoplasmic in Cstb-knockdown cells, in comparison to the Neg-siRNA 
transfected cells, where it was located both in the cytoplasm and in the nucleus. The 
mock-transfected cells, used as reference, had a more even intracellular distribution of 
the STAT1 protein in comparison to the Cstb- and the Neg-siRNA transfected cells. 
 
4.2.6.2. Signal transducer and activator of transcription (Stat2) 
In response to Cstb knockdown, the Stat2 mRNA expression levels were increased in a 
similar way as Stat1 (Figure 24). An upregulation in Stat2 mRNA levels was detected in 
both Cstb-siRNA and Neg-siRNA transfected cells at the time point 36 hours (fold 
changes 3.1 and 1.5, respectively). At the time point 48 hours, both samples decreased 
in Stat2 expression (fold changes 1.2 and 1.3, respectively), and continued decreasing 
until the time point 60 hours (fold changes for both 0.85). An increase in Stat2 
expression was detected for both samples at the time point 72 hours (fold changes 
0.98 and 1.65), and at 96 hours there were only minor changes between the 
transfected samples (fold changes 1.0 and 1.1). 
A) B) C) 
Figure 23. STAT1 (green) expression was downregulated at 96 hours in the Cstb 
knockdown cells (A) compared to the negative control (B), and the mock-transfected cells 
(C). An altered cellular distribution of the STAT1 protein was also observed in the Cstb 
knockdown cells. The nuclei of the cells are stained with Hoechst (blue).  
Scale 10 µm. 
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Figure 24.  The mouse Stat2 mRNA expression in differentially transfected RAW264.7 
cells. A peak in upregulation of Stat2 expression was observed in Cstb knockdown cells (blue) 
at the time point 36 hours (fold change 3.1), after which the Stat2 expression levels started to 
decrease, reaching the lowest expression level at the time point 60 hours (fold change 0.8). At 
72 and 96 hours the Stat2 expression level had normalized to the control level. In the Neg-
siRNA transfected cells (grey), the Stat2 mRNA expression levels varied in the range from 0.85 
to 1.65.The expression values were obtained from TaqMan using the Pflaffl –method and the 
expression of Stat2 was normalized to the expression levels of Tbp. The expression levels are 
shown in relation to mock-transfected cells. Measurements were performed three 
independent times, and the error bars represent the standard deviations (SD). P-values are 
marked above the bars. The + - and the – -signs at the lower panel indicate which siRNA the 
cells have, and have not been transfected with. 
 
The STAT2 expression was analyzed by WB, which presented similar results as seen on 
mRNA level (Figure 25). In Cstb knockdown cells, the STAT2 protein was upregulated at 
the time points 36, 48 and 60 hours. At the time point 72 hours a downregulation of 
STAT2 was detected (fold change 0.7). In Neg-siRNA transfected cells the STAT2 
protein expression was similar as in the Cstb knockdown cells, but an upregulation of 
STAT2 was observed at the time point 60 hours (fold change 2.7). 
 
 
65 
 
 
 
Figure 25. A. Western blot analysis of the STAT2 expression in RAW264.7 cells. STAT2 
(113 kDa) upregulation was detected in Cstb knockdown cells (Cstb-siRNA) at the 36 and 48 
hour time points. Neg-siRNA transfected and untreated cells presented with an upregulation 
of STAT1 at the 60 hour time point. β-tubulin (55 kDa) was used as loading control. The 
proteins are indicated on the left, and their molecular weights (kDa) on the right. The time 
points are indicated above the lanes. B. Quantification of the Western blot by the Odyssey 
software. As observed in Fig. 25a, STAT2 was slightly upregulated in Cstb knockdown cells 
(blue) at all but the 72 hour time point. The Neg-siRNA (grey) transfcted cells follow the kinetic 
profile of STAT2 expression, with the exception of the time point 60 hours, when STAT2 
expression levels are increased. Expression of STAT2 is shown in relation to mock-transfected 
cells. The + - and the – -signs at the lower panel indicate which siRNA the cells have, and have 
not been transfected with. 
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4.2.6.3. Interferon regulatory factor 9 (Irf9) 
Irf9 mRNA expression did not change in a substantial manner during the examined 
time points. The Irf9 mRNA expression was slightly upregulated after transfection 
(Figure 26) in Cstb knockdown cells and remained upregulated (fold change 1.1) until 
the time point 60 hours. A downregulation of Irf9 mRNA was detected at the time 
point 72 hours (fold change 0.9), and the expression levels stabilized to the level of 
mock-transfected cells by 96 hours. Neg-siRNA transfected cells expressed Irf9 in a 
similar manner, however, with increased expression levels at 48 hours (fold change 
1.65). 
 
Figure 26. The mouse Irf9 mRNA expression in differently transfected RAW264.7 cells. 
A slight increase of Irf9 in the Cstb knockdown (purple) and in the Neg-siRNA (grey) 
transfected cells was detected, followed by a decrease in expression after 60 hours. The Irf9 
expression levels were downregulated at the 72 hour time point, increasing at 96 hours to the 
levels of the mock-transfected cells. The expression values were obtained from TaqMan using 
the Pflaffl –method and the expression of Irf9 was normalized to the expression levels of Tbp. 
The expression levels are shown in relation to mock-transfected cells. Measurements were 
performed three independent times, and the error bars represent the standard deviations 
(SD). P-values are marked above the bars. The + - and the – -signs at the lower panel indicate 
which siRNA the cells have, and have not been transfected with. 
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The expression levels of IRF9 were detected by WB analysis (Figure 27). An initial 
increase in IRF9 expression was observed in all samples after the 12 hour time point, 
however, the time point specific changes in protein expression were small. The 
expression levels of IRF9 in Cstb knockdown cells remained downregulated (fold 
change 0.7) until the time point 60 hours, when an upregulation was detected (fold 
change 1.2). At the following time points, the expression levels of IRF9 were 
downregulated to 0.8. The negative control samples were equally downregulated, 
except at the time point 48 hours, being upregulated by 1.1 fold. 
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Figure 27. A. Western blot analysis of the IRF9 expression in RAW264.7 cells. IRF9 (48 
kDa) expression remained rather vaguely expressed in Cstb knockdown cells throughout all 
time points. Neg-siRNA transfected cells presented with a similar expression pattern of IRF9 as 
the Cstb knockdown cells. β-tubulin (55 kDa) was used as loading control. The proteins are 
indicated on the left, and their molecular weights (kDa) on the right. The time points are 
indicated above the lanes. B. Quantification of the Western blot by the Odyssey software. 
The detected changes in IRF9 expression were small between Cstb knockdown (purple) and 
Neg-siRNA (grey) transfected cells. An increase in IRF9 expression was detected at the time 
points 60 hours for Cstb-siRNA (fold change 1.2), and 48 hours for the Neg-siRNA (fold change 
1.1) transfected cells. The expression level decreased to 0.8 at the time point 72 hours for Cstb 
knockdown cells. Expression of IRF9 is shown in relation to mock-transfected cells. The + - and 
the – -signs at the lower panel indicate which siRNA the cells have, and have not been 
transfected with. 
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4.2.7. The effects of Cstb knockdown on markers for oxidative stress 
In order to test whether markers for oxidative stress were increased in Cstb 
knockdown cells, WB analysis of the iNOS protein and subsequent nitric compound 
release measurements were performed. 
4.2.7.1. Inducible nitric oxide synthase (iNOS) 
The iNOS expression was detected by WB analysis (Figure 28) from the transfected 
and the control cells. The only iNOS positive signals were perceived from the 
untreated control and Neg-siRNA transfected cells, cellular samples which presented 
with morphological changes already previously, and collected at the time-point 60 
hours post-transfection. 
 
Figure 28. Western blot analysis of the iNOS protein. iNOS (130 kDa) was detected only 
in the untreated control cells and the Neg-siRNA transfected cells from the time point 60 
hours. No other sample was positive for iNOS expression. STAT1 (84/91 kDa) expression is 
shown as marker for the other samples. 
 
The iNOS expression was evaluated also by IF microscopy (Figure 29). In Cstb 
knockdown cells, the iNOS positive cells increased in amount over time and at the final 
time point, 96 hours, a maximal amount of iNOS positive cells, about 20 per coverslip, 
was detected. A difference in the amount of iNOS positive cells between the Cstb-
siRNA and Neg-siRNA transfected cells was, however, not observed. No iNOS positive 
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cells were detected in the mock-transfected cells at any time point. LPS activated 
RAW264.7 macrophages (kind gift from I. Körber, group A-E. Lehesjoki, Helsinki, 
Finland) were used as positive control for iNOS detection, and those cells expressed 
iNOS up to 85%. The activated macrophages are bigger in size and they possess 
different morphological features, such as a round, outspread phenotype, which is not 
seen in naïve RAW264.7 cells. 
 
Figure 29. The iNOS (green) protein expression was altered at 96 hours in the Cstb 
knockdown cells. Cstb knockdown cells (A) presented with an unpregulation in iNOS 
expression, when compared to mock-transfected cells (B). A similar amount of iNOS positive 
cells was, however, observed in the Neg-siRNA transfected cells (not shown). LPS-activated 
RAW264.7 macrophages (C) were used as a positive control for iNOS detection. Besides 
increased iNOS expression, a clear morphological phenotype was observed in the LPS 
activated control cells. The nuclei of the cells are stained with Hoechst (blue).  
Scale 10 µm for A and B, 50 µm for C. 
 
4.2.7.2. The Griess test 
Release of nitric compounds from the transfected and control RAW264.7 cells was 
measured from the growth media by the Griess test. All test results, apart from the 
untreated control and Neg-siRNA transfected cells at the 60 hour time-point, were 
negative for nitrite release. The growth media from the untreated control and Neg-
siRNA transfected cells was collected from the same cell culture flasks as the 
corresponding protein lysates were taken from. 
 
A) B) C) 
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4.2.8. Summary of the most important findings 
Knockdown of Cstb in RAW264.7 cells resulted in an initial upregulation of all 
examined genes (Figure 30), before a downregulation of Stat1 and Stat2 became 
prominent. Transfection with the Cstb-siRNA was both sensitive and specific, and the 
kinetics of the Cstb mRNA and CSTB protein showed at what time points the 
downregulation was maximal. At the same time point when CSTB protein expression 
was at its lowest, a decrease in Stat1 and Stat2 mRNA expression became detectable 
by qRT-PCR. This downregulation was later observed also on protein level. 
 
Figure 30. Timeline of findings at different time points in the Cstb knockdown 
RAW264.7 cells. The timeline describes the findings between Cstb-siRNA transfection until 96 
hours. The timeline contains changes both on mRNA and protein level, and links the changes 
together. A transition from Cstb to Stat1 and Stat2 happened at the time point 48 hours, when 
the CSTB protein and the Stat1 and Stat2 mRNA were downregulated to their minimum. 
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5. DISCUSSION 
The chronic changes of EPM1 have so far been studied in patient cells and tissues and 
in the Cstb-/- mouse. Patient samples are, however, hard to obtain, and the existing 
mouse model breeds poorly. Therefore, there has been a need for an in vitro model, in 
which the acute pathogenesis of the disease could be further investigated on 
molecular level. 
In the present work, we employed RNA interference (RNAi) to create a cystatin B 
(Cstb) -knockdown model in the human HeLa and the murine macrophage RAW264.7 
cell lines. We also utilized these cell models to study the members of the JAK/STAT 
signaling pathway, which had previously been shown to be affected in the primary 
microglia of Cstb-/- mice (Körber et al, unpublished). 
We used siRNA transfection to transiently downregulate the Cstb mRNA, and based on 
the kinetics of CSTB knockdown, we hypothesized the timeframe when changes in the 
expression of the members of the JAK/STAT signaling pathway could be detected. For 
further validation of the method in EPM1 pathophysiology, we also looked for markers 
of oxidative stress, which has previously been reported to co-occur in Cstb-/- mice 
(Lehtinen et al, 2009). 
 Transfection in HeLa and RAW264.7 cells 5.1.
Knockdown of CSTB was first conducted in the cell line HeLa. The cell line was chosen 
as part of this experiment in order to optimize the method in an easily manipulated 
cell line, but also to compare the cell line specific effects of CSTB knockdown. The 
manufacturer of the electroporation kit provided us with a readily optimized protocol 
for HeLa transfection. We chose to transfect a GFP encoding plasmid (pEGFP) together 
with the CSTB-siRNA in order to determine a percentual transfection efficiency by IF 
microscopy of the GFP protein. Transfection was easy, cell mortality was low, and IF 
stainings showed that the transfection efficiency was over 50%. By performing WB 
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analysis of protein lysates from the HeLa cells, we also observed that CSTB was 
effectively downregulated by the siRNAs. 
The cell line RAW264.7 was chosen for this study due to its monocytic origin. The cell 
line is used in several immunological studies, and it is relatively easy to maintain. The 
manufacturer of the electroporation kit had an optimized protocol for transfection of 
this cell line, but the obtained transfection efficiency was not as high as reported in 
the protocol. Further re-optimization had been published by another research group 
(Yunus et al, 2010), but despite replicating the experiment with the reported 
parameters, we did not obtain similar results. We had to optimize the protocol by 
adjusting cell and siRNA amounts, which finally lead to transfection efficiency of over 
80%. The siRNA molecules we used for transfecting RAW264.7 cells were labelled with 
an Alexa Fluor-647 fluorochrome, which enabled us to monitor the transfection 
efficiency without conducting laborious and time-consuming IF-stainings. Since there is 
unfortunately no proper antibody against the mouse CSTB protein, we were not able 
to study the downregulation of CSTB on cell-specific level. QRT-PCR and WB analysis, 
however, showed that the siRNA sequence that we used was sensitive for Cstb mRNA, 
and downregulated it almost completely. 
 CSTB knockdown in HeLa cells did not result in changes in the 5.2.
JAK/STAT signaling pathway 
Downregulation of CSTB mRNA by siRNA transfection was shown to be efficient in 
HeLa cells. However, effects of CSTB knockdown in the expression levels of members 
of the JAK/STAT signaling pathway, such as STAT1 and STAT2 were not detectable on 
protein level. These results may be explained by the tissue specific consequences of 
CSTB knockdown. In EPM1 patients, histopathological changes have been described 
only in the brain and the bones (Cohen et al, 2011; Eldridge et al, 1983; Haltia et al, 
1969; Korja et al, 2007; Koskenkorva et al, 2009; Koskenkorva et al, 2012; Koskiniemi 
et al, 1974; Suoranta et al, 2012), even if the CSTB protein is ubiquitously expressed 
(Alakurtti et al, 2005; Brännvall et al, 2003; Laitala-Leinonen et al, 2006). Changes in 
STAT1 and STAT2 expression in HeLa cells require interferon stimulation in order to 
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become detectable by WB, as observed from previous literature (Nishio et al, 2001). 
Based on these observations, we concluded that the cell line HeLa was not a good tool 
in our study for investigating gene specific changes of monocytic origin. However, the 
cell line HeLa was used to optimize the RNAi method, which we applied when 
continuing the study in RAW264.7 cells. 
 Cstb knockdown in RAW264.7 cells 5.3.
5.3.1. The specificity of the Cstb-siRNA and the kinetics of Cstb 
In the RAW264.7 cell line, siRNA transfection and Cstb knockdown were successful, 
which could be visualized by IF microscopy, and monitored by qRT-PCR and WB 
analysis. The Cstb mRNA was downregulated to its minimum at 12 hours post 
transfection, thereafter the expression level rapidly increased. The optimal siRNA 
incubation time is generally considered to be 24-72 hours depending on cell type and 
gene to be silenced (Mirus Bio, 
 http://www.mirusbio.com/tech_resources/tips/optimize_sirna_transfection). 
However, in our case the Cstb expression levels had exceeded 10% already at the time 
point 36 hours and showed an increased expression (50%) at 72 hours. Therefore, the 
time frame when Cstb expression levels were comparable to those measured from the 
cultured primary microglia of the Cstb-/- mouse (Körber et al, unpublished), which this 
work is based on, was rather narrow. 
The mRNA of Gapdh was knocked down as positive control and to rule out unspecific 
effects of Cstb inhibition. Gapdh expression levels remained downregulated for a 
longer time period, demonstrating the gene-specific differences of RNAi. The kinetics 
was, however, similar between the mRNAs, both being most downregulated at 12 
hours and increasing in expression after that. The similar kinetics between the Cstb 
and Gapdh mRNA implied that Gapdh was a good positive control for our study. 
We did not observe significant variation in Cstb expression levels in the Gapdh-siRNA 
transfected cells. Some changes in Cstb expression were, however, detected in the 
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Neg-siRNA transfected cells. This raised a question whether the Neg-siRNA sequence 
could somehow affect Cstb mRNA expression. This could unfortunately not be further 
investigated due to the proprietary sequence of the Neg-siRNA. 
The duration for translation of mRNA to protein is both gene and tissue specific 
(Wilusz & Wilusz, 2004). There is no published data about the life span of the CSTB 
protein in macrophages, but, based on our kinetic profiles of the Cstb mRNA and the 
CSTB protein, it is around 30 hours in the cell line RAW264.7.  
Downregulation of CSTB was not as effective on protein as on mRNA level, which 
endogenous siRNA inhibitors and dilution of siRNA concentration in the cells due to 
cell proliferation contributes to in a high degree (Rao et al, 2009a; Sandy et al, 2005). 
Moreover, the extrapolation from mRNA levels to protein abundance involves several 
cellular processes, and is not as straight forward as it appears (Brewer, 2002). 
Due to our hypothesized CSTB life span, we expected to detect changes in expression 
of members of the JAK/STAT signaling pathway at the later time points, first on mRNA 
level and later, depending on the half-life of the target protein, on protein level.  
5.3.2. Cstb downregulation had an effect on Stat1, Stat2, and Irf9 
Downregulation of Cstb affected the expression levels of Stat1, Stat2, and Irf9 in 
RAW264.7 cells, as previous results had shown in Cstb-/- microglia (Körber et al, 
unpublished). After detection of Cstb knockdown, there was an initial increase in the 
expression levels of Stat1, Stat2, and also somewhat on Irf9. These changes were also 
detected in the Neg-siRNA, but not in the Gapdh-siRNA transfected cells. We had 
previously observed that the Neg-siRNA sequence affects the expression levels of Cstb, 
proposing that the response pathway after Neg-siRNA transfection involves at least to 
some extent Cstb. Without the Gapdh-siRNA control, these changes would have been 
considered unspecific and due to transfection. 
A decrease in the mRNA expression levels of Stat1 and Stat2 was detected by qRT-PCR 
at the time point 48 hours, at the same time point when CSTB protein expression was 
downregulated to its minimum, further suggesting interplay between CSTB and the 
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Stats. Downregulation of Gapdh, which we assumed would not affect the JAK/STAT 
signaling pathway, did not change expression levels of either Cstb or Stat1 at any of 
the measured time points. The Neg-siRNA transfected cells showed, however, similar 
kinetics of Stat1 and Stat2 mRNA expression as the Cstb knockdown cells, suggesting 
that the response of the Stats was unspecific. Due to fluctuations in the Cstb mRNA 
expression levels in the Neg-siRNA transfected cells, this remains, however, 
unresolved. 
The rather late time point (60 hours) when the Stats were downregulated on mRNA 
level implied that we would perhaps not be able to detect any changes on protein 
level. Literature revealed that the life span of the STATs is >24 hours i.e. in the 
lymphoblastic cell line Daudi (Lee et al, 1997; Lee et al, 2011), delaying the time point 
for detecting downregulation on protein level to >70 hours. Downregulation was, 
however, observed at the time points 72 and 96 hours for STAT2 and STAT1, 
respectively. Within this time frame, siRNA dilution is evident, and most of the 
cultured cells are untransfected daughter cells, resulting in less prominent 
downregulation on protein level when compared to the previously obtained mRNA 
expression levels.   
Changes in Irf9 expression were not as evident as with the Stats. Similarly as with the 
Stats, an increase in Irf9 mRNA expression was observed, but it was apparently 
transfection dependent, as has been previously reported (Li et al, 2005). After CSTB 
downregulation, a minor decrease was, however, observed in Irf9 expression levels, 
further supporting the involvement of Cstb in the members of the JAK/STAT signaling 
pathway. 
The statistical analyses were performed with expression values from the Neg-siRNA 
transfected cells as control dataset. Considering that there was similar variation in 
mRNA expression levels obtained from the Neg-siRNA transfected cells as in Cstb 
knockdown cells, the control set-up was not optimal. This fact does, however, not 
affect the results as such, only the obtained P-values. Due to unchanged expression 
values of Cstb and Stat1 in the Gapdh-siRNA transfected cells, this dataset would have 
been a better choice for control. Unfortunately, qRT-PCR analyses beyond Cstb and 
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Stat1 in Gapdh knockdown cells were not performed, which would have limited our 
results to these genes. 
5.3.3. Morphologically active cells had increased CSTB, STAT1, STAT2, and iNOS 
expression 
While performing the time point experiments, two sets of samples, Neg-siRNA 
transfected cells and untreated control cells, aimed for protein extraction, presented 
with morphological changes at the 60 hour time point, indicating an activated 
phenotype. Activated macrophages grow in size and start proliferating, but they also 
secrete cyto- and chemokines, NO, and growth factors (Brown & Neher, 2010; Czeh et 
al, 2011), which are known to activate other macrophages (Liu et al, 1998b). 
Transfection of bacterial and mammalian DNA to RAW264.7 cells has been reported to 
activate the cells (Jiang et al, 2004; McCoy et al, 2004), but synthetic siRNA sequences 
below 30 nucleotides should overcome this problem (Elbashir et al, 2001). We did not 
observe activation of cells in any of the other samples, indicating a sporadic event due 
to external stimuli. 
In these morphologically active samples, an upregulation of the proteins CSTB, STAT1, 
and STAT2 was detected by WB analysis. This was contrary to the findings on mRNA 
level, which we used naïve samples for, but in concordance with literature about the 
first line defense against pathogens (Darnell et al, 1994; Liu et al, 1998b; Liu et al, 
1998b), and the observation that CSTB is upregulated in RAW264.7 cells as response to 
LPS activation (24h) (Körber et al, unpublished).  
The immunoeffector molecules, which the activated macrophages secrete, include NO, 
indirectly implying increased iNOS expression. iNOS catalyzes the production of NO, 
which gets secreted from the cell and activates other macrophages. Nitric compounds 
were measured from the growth media by the Griess test, and iNOS expression was 
analyzed by WB. Only the morphologically active samples (Neg-siRNA transfected and 
untreated control cells, 60h) were positive for the Griess test and iNOS expression. The 
signaling event for activating other macrophages includes the JAK/STAT signaling 
pathway, which induces iNOS expression. The increased sensitivity for oxidative stress 
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in Cstb deficient cells might, however, not be directly dependent on the JAK/STAT 
signaling pathway, but rather on an imbalance in the redox homeostasis (Lehtinen et 
al, 2009), which is necessary not an instant effect of Cstb knockdown, but require 
chronic Cstb downregulation to be detected. 
5.3.4. Conclusions and future work 
The conducted study consisted of two parts, firstly to set up a siRNA based method to 
knock down the Cstb mRNA in two different cell lines, and secondly to compare its 
effects on the interferon regulated genes of the JAK/STAT signaling pathway. 
Knockdown of Cstb was successful in both cell lines HeLa and RAW264.7. Because 
changes in Stat1, Stat2, Irf9, and iNOS could only be seen in the murine macrophage 
cell line RAW264.7, these cells were mainly used for conducting the second part of the 
study.  
Our working hypothesis was based on microarray results from primary microglia of 
Cstb-/- mice (Körber et al, unpublished). The cell line RAW264.7 is despite its monocytic 
origin not directly comparable with microglia, which possibly contributed to the 
results. The kinetics of Cstb downregulation revealed that the actual timeframe of Cstb 
knockdown by siRNA inhibition is narrow, and one of the future plans based on these 
results is the creation of a stable knockdown of Cstb in RAW264.7 cells.  
Downregulation of the members of the JAK/STAT signaling pathway in the Cstb 
knockdown cells seem to verify our working hypothesis. However, in order to confirm 
the specificity of the downregulation to Cstb knockdown cells, a Cstb-rescue 
experiment, outside the frame of this thesis, is being conducted. In the future, siRNA 
mediated Cstb knockdown will be extended to study the direct consequences of CSTB 
downregulation also in neurons. 
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APPENDICES 
Reagents used in cell culture: 
Phosphate buffered saline (PBS), 0.01 M (1x) (Liuoslaboratorio, Biomedicum, 
Helsinki, Finland) 
 NaCl, 137 mM 
 KCl, 2.7 mM 
 Na2HPO4, 10 mM 
 KH2PO4, 1.8 mM 
 H2O, up to desired volume 
 
Reagents used in transfection: 
Transfection media, 500 ml 
DMEM with 4.5 mg/l D-glucose (Lonza, Stockholm, Sweden) 
L-glutamine, 1x 
Sodium pyruvate, 110 mg/l (Lonza, Stockholm, Sweden) 
FBS, 10% 
 
Reagents used in reverse transcription of RNA to cDNA and the S15 gene polymerase 
chain reaction: 
 Primer sequences for S15-PCR 
S15 F 5’-TTCCGCAAGTTCACCTACC-3’ (Sigma-Aldrich, Helsinki, Finland) 
S15 F 5’-CGGGCCGGCCATGCTTTACG-3’ (Sigma-Aldrich, Helsinki, Finland) 
 
Reagents used in protein extraction: 
1x Cell lysis buffer 
NaCl, 250 mM (Sigma, Steinheim, Germany) 
Na3VO4, 100 mM (Sigma, Steinheim, Germany) 
NaF, 50 mM (Sigma, Steinheim, Germany) 
DTT, 1 mM (Fisher-Scientific, Loughborough, UK) 
Protease inhibitor, diluted to 1x (Roche Diagnostics, Espoo, Finland) 
2x NP-40 lysis buffer, diluted to 1x 
H2O, up to desired volume 
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2x NP-40 lysis buffer 
NP-40, 1% (Merck, Darmstadt, Germany) 
Tris, pH 8.0, 100 mM (Sigma, Steinheim, Germany) 
Glycerol, 20% (Sigma, Steinheim, Germany) 
EDTA, 200 μM (Riedel-de-Haen, Seelze, Germany) 
 
Reagents used in SDS-polyacrylamide gel electrophoresis (SDS-PAGE): 
5x Laemmli buffer, 100 ml 
Glycerol, 15 ml (Sigma, Steinheim, Germany) 
Tris-HCl, 0.5M, pH 6.8, 15 ml (Sigma, Steinheim, Germany) 
SDS, 20% (w/v), 10 ml (Sigma, Steinheim, Germany) 
Bromophenol Blue, 15 mg (Merck, Espoo, Finland) 
H2O, up to 100 ml 
 
1x SDS-PAGE electrophoresis running buffer (Liuoslaboratorio, Biomedicum, 
Helsinki, Finland) 
 Tris, 25 mM 
 Glycine, 192 mM 
 SDS, 0.1% 
 H2O, up to desired volume 
 
Reagents used in Western blot: 
Ponceau S, 2%, 100 ml 
Ponceau S, 2g (Sigma, Steinheim, Germany) 
Trichloracetic acid, 30g (Merck, Darmstadt, Germany) 
Sulfosalicylic acid, 30g (Riedel-de-Haen, Seelze, Germany) 
H2O, up to 100ml 
 1x Tris-glycine transfer buffer (Liuoslaboratorio, Biomedicum, Helsinki, Finland) 
 Tris, 25 mM 
 Glycine, 192 mM 
 H2O, up to desired volume 
  +20% MeOH 
 
